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Abstract
Fam83d and Dupd1 have been identified as novel genes in skeletal muscle that are upregulated
in response to neurogenic atrophy in a mouse model. qPCR analysis reveaed both genes are
expressed in skeletal muscle with Fam83d expression being highest during myoblast
proliferation, while Dupd1 expression is highest during myotube differentiation. Overexpression
of either protein results in inhibition of proper muscle cell differentiation as evidenced by
repression of both myosin heavy chain and myogenin expression. Characterization of
transcriptional activity revealed both genes are modulated by myogenic regulatory factors and
additionally, Dupd1 expression is enhanced by dexamethasone treatment. Assessment of
subcellular localization revealed that Fam83d localizes in a punctate manner in the cytoplasm,
while the expression of Dupd1 showed ubiquitous distribution throughout the cell. To assess
function, Fam83d or Dupd1 were ectopically overexpressed in cultured muscle cells.
Overexpression of Fam83d resulted in significant repression of phosphorylated ERK and AKT.
Interestingly, inhibition of the 26S proteasome and the MAP kinase signaling pathway both
resulted in stabilization of Fam83d during muscle cell differentiation. Finally, Fam83d has a
putative phospholipase D-like domain that appears to be necessary for destabilizing casein kinase
Iα and inhibiting ERK phosphorylation in cultured myoblasts. Overexpression of Dupd1 resulted
in significant repression of phosphorylated ERK and AMPK. Additionally, Dupd1
overexpression resulted in dramatic increases in GR protein as well as phosphorylated GR, while
attenuating activity of a GRE reporter gene. The discovery that Fam83d and Dupd1 are
expressed in skeletal muscle combined with the observation that they are induced in response to
neurogenic atrophy helps further our understanding of the molecular and cellular events of
skeletal muscle wasting
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Chapter 1: Background on skeletal muscle atrophy, MuRF1 and cell signaling
Skeletal Muscle Atrophy
Muscle atrophy is identified as the reduction in muscle mass and strength. Muscle mass is
maintained by a balance between protein synthesis and protein degradation. When protein
degradation outpaces synthesis, atrophy occurs (1). Atrophy can result from a variety of
conditions including aging, spinal cord injury, immobilization, corticosteroid exposure, and
denervation (2). Many molecular pathways contribute to muscle degradation, but the full scope
of these pathway interactions is still unclear. Additional research into muscle degradation
mechanisms, such as the ubiquitin proteasome system, will help further elucidate these pathways
and may identify possible targets for future therapeutic intervention.

The Ubiquitin Proteasome System
The ubiquitin proteasome system (UPS) is one pathway that participates in muscle degradation.
This pathway consists of three proteins, the E1 ubiquitin activating enzyme, the E2 ubiquitin
conjugating enzyme and the E3 ubiquitin ligase. A ubiquitin molecule first binds to a cysteine
residue on the E1 enzyme. The ubiquitin is then transferred to a cysteine residue on the E2
enzyme. The E2 enzyme transfers the ubiquitin to the target substrate to tag it for degradation.
This transfer is regulated by the E3 ubiquitin ligase which has a binding site for both the E2
enzyme and a binding site that is substrate specific (3). The E3 enzyme is crucial as it provides
selectivity and specificity to the UPS. The conjugation and ubiquitin transfer continues until the
substrate accumulates a chain of four or more molecules of ubiquitin which initiates degradation
by the 26s proteasome (Fig. 1).
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Figure 1. Schematic of the ubiquitin proteasome system. The E1 ubiquitin activating enzyme, E2
ubiquitin conjugating enzyme and E3 ubiquitin ligase form a pathway to ubiquinate substrates
for degradation by the 26s proteasome (4).
MuRF1 and MAFbx
Since E3 ubiquitin ligases provide specificity for the ubiquitin proteasome system, identifying
muscle specific E3 ubiquitin ligases is a critical component of understanding muscle atrophy
pathways. In 2001, a study by Bodine et al identified muscle RING finger 1 (MuRF1) and
muscle atrophy F-box (MAFbx) as universal markers of muscle atrophy (2). In the study, rats
were subjected to denervation, hind limb suspension, and immobilization. Muscle tissue was
then isolated and analyzed for genes showing differential expression between atrophy and
control conditions in wild-type animals (2). Many genes showed differential regulation in one or
two of the conditions but only MuRF1 and MAFbx were upregulated in all three conditions (Fig.
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2). Knockout mice were produced to further examine the role of these two genes and in both
cases the knockout mice were atrophy resistant compared to control animals (2). MuRF1
knockouts exhibited 36% muscle sparing and MAFbx knockouts exhibited 56% muscle sparing
as compared to control (2). While MAFbx knockouts showed a greater percentage of muscle
sparing, the MuRF1 knockouts showed greater muscle integrity making MuRF1 the preferred
subject for further study (2). The structure of MuRF1 suggests its role as an E3 ubiquitin ligase
but to date there has been a lack of clearly identified protein targets (1), which leads to further
questions about MuRF1’s role in muscle atrophy.

Figure 2. Northern blot displaying mRNA expression of MuRF1 and MAFbx in muscle tissue of
rats subjected to atrophy induction by immobilization, denervation, and hind limb suspension.
Expression is observed at day 1 and reaches a peak at day 3 post denervation (2).
MuRF1 as a Transcriptional Regulator
In 2013, Furlow et al. investigated MuRF1’s role in muscle atrophy more closely using genomewide microarray analysis (5). Knockout mice were produced by inserting a β-galactosidase lacZ
cassette into the MuRF1 gene (2). This insert disrupted the function of the MuRF1 gene and
produced β-galactosidase when the MuRF1 promoter is active. This construct allowed researches
to assess endogenous MuRF1 promoter activity without the effect of the functional MuRF1 gene.
3

They compared MuRF1 knockout and control mice under neurogenic atrophy conditions and
control conditions by harvesting gastrocnemius muscle at 3 and 14 days post-denervation (5). A
microarray analysis was then performed on harvested muscles to identify genes with differential
expression at early (3 days) and late (14 days) stages of denervation. In the wild-type (WT) mice,
MuRF1 expression was elevated at day 3 post-denervation but returned to baseline by day 14. In
the knockout KO) animals, β-galactosidase expression was also elevated at day 3 but remained
elevated at day 14, suggesting that MuRF1 may be negatively regulating its own expression (Fig.
3).

Figure 3. Transcriptional activity of the MuRF1 gene locus in WT and MuRF1 KO mice
following sciatic nerve transection. (A) Denervated WT mice showed an increase in MuRF1
gene expression at day 3 (3D), but returned to baseline at day 14 (14D) post-denervation. (B)
Denervated KO mice showed at increase in β-galactosidase expression, which is under the
control of the MuRF1 promoter, at day 3 and expression remained elevated at day 14 postdenervation (5).
In addition, MAFbx expression varied between the wild-type and MuRF1 knockout mice.
Denervated wild-type mice showed increased MAFbx expression at day 3 and expression
returned to baseline by day 14 (Fig. 4). However, in the MuRF1 knockout mice, MAFbx
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expression was elevated at day 3 and remained elevated at day 14 (Fig. 4). This suggests that
MuRF1 may also be negatively regulating MAFbx expression (5).

Figure 4. Transcriptional activity of MAFbx in wild-type and MuRF1 KO mice following sciatic
nerve transection. (A) Denervated WT mice showed an increase in MAFbx gene expression at
day 3 (3D), but expression returned to baseline at day 14 (14D) post-denervation. (B) Denervated
MuRF1 KO mice showed an increase in MAFbx gene expression at day 3 and it remained
elevated at day 14 post-denervation (5).
Differences in expression were shown for a wide variety of genes when comparing the wild-type
and MuRF1 knockout mice subjected to atrophy conditions. One of these genes, Family with
Sequence Similarity 83 D (Fam83d) is the subject of chapter 2, while Dual specificity
phosphatase and pro isomerase domain containing 1 (Dupd1), is the focus of chapter 3 of this
thesis.

Myogenic Regulatory Factors (MRFs)
Myogenic Regulatory Factors (MRF) are transcription factors important to the development of
muscle tissue and are dramatically upregulated in response to neurogenic atrophy. MRFs
function by interacting with co-activators and co-repressors within the promoter region of
muscle-specific genes (6,7). MRFs are characterized by the presence of a basic helix-loop-helix

5

motif, which promotes binding to a canonical E-box consensus sequence of 5’-CANNTG-3’
(where N can be any nucleotide). These E-box sequences are found in the promoter regions of
most muscle-specific genes, which includes MuRF1 and MAFbx. MRFs can bind directly to
these E-boxes and modulate the transcriptional activity of genes that possess these enhancers
(6,7).

MyoD and myogenin are two such MRFs that have previously been shown to be upregulated
during neurogenic skeletal muscle atrophy (7). MyoD acts as a marker of myogenic commitment
to skeletal muscle and is important in maintaining the differentiated state of the cells. It is also
required for the expression of myogenin, which plays a significant role in muscle cell
differentiation and viability (7). Myogenin is also required for full induction of MuRF1 and
MAFbx under neurogenic atrophy conditions (8). In fact, previous studies have shown that
deletion of myogenin leads to a reduction of MuRF1 and MAFbx and subsequent resistance to
muscle wasting in mice following denervation (8).

Signal Transduction Pathways Involved in Muscle Growth and Development
Atrophy is an active process, requiring transcriptional activation and differential regulation of a
wide variety of genes (9). This can occur through regulation by one or more signaling pathways
that regulate myogenesis, protein synthesis, and protein degradation (9). MAP kinase signaling is
an important pathway involved in cell growth, proliferation, and differentiation in a wide variety
of tissue types (10). The pathway consists of four main branches including, the ERK1/2, p38,
JNK and ERK5 arms (10). Within each of these branches, growth factor binding to receptor
tyrosine kinases triggers a signaling cascade that leads to phosphorylation and activation of
MAP kinase kinase kinases (MAP3Ks), which in turn phosphorylate MAP2Ks to activate them,
6

which then in turn activates MAPKs by phosphorylation as well (10). Each branch triggers a
unique terminal kinase to translocate to the nucleus to act as a transcription factor to modulate
the activity of a subset of genes (11). ERK signaling plays a critical role in muscle cell
proliferation and repression of premature differentiation through prevention of early cell cycle
exit (11). While ERK signaling is reduced as muscle cells differentiate, ERK1/2 activity has been
shown to increase again during terminal differentiation and has been found to be critical for
proper myocyte fusion and survival (12). ERK1/2 signaling likely has a role to play in skeletal
muscle atrophy as evidenced by improved myogenesis and reduced muscle wasting in cachexic
mice following treatment with PD98059, an ERK-specific inhibitor (13).

Figure 5. Illustration of MAPK cascades for ERK1/2, JNK, p38, and ERK5. (14).
Previous research also suggests that the AKT signaling pathway is important in muscle atrophy
and hypertrophy depending on the state of the tissue (11). Activated by insulin-like growth factor
(IGF), AKT functions to activate expression of pro-survival proteins, such as mTOR, and
7

suppresses expression of apoptotic proteins, such as those in the FoxO family (15). AKT is
capable of phosphorylating mTOR which increases activity of downstream targets involved in
protein synthesis (16). Dephosphorylation of FoxO proteins leads to FoxO translocation to the
nucleus where it binds to FoxO binding elements (FBE) in the promoter region of various genes
related to skeletal muscle atrophy (17). AKT phosphorylation of FoxO proteins leads to
cytoplasmic sequestration and blockage of the activation of atrophy-inducing genes, such as
MuRF1 (17).

Figure 6. The insulin-like growth factor 1 (IGF1)-Akt pathway controls muscle growth via
mammalian target of rapamycin (mTOR) and FoxO proteins. (16)
Glucocorticoid (GC) signaling is known to play a role in skeletal muscle atrophy (18,19).
Increases in GCs lead to decreases in protein synthesis and increases in protein degradation (19).
The inactive glucocorticoid receptor is found in the cytoplasm bound to a chaperone complex
containing several proteins including heat shock protein 90 (HSP90) (20). As a ligand-dependent
8

transcription factor, binding of GCs result in the cytoplasmic glucocorticoid receptor (GR) to
translocate to the nucleus where it may bind to glucocorticoid response elements (GRE) (19). GR
possesses multiple phosphorylation sites and a dynamic interplay between phosphorylation and
dephosphorylation events determines its precise role following nuclear translocation (20). In
addition to transcriptional enhancement though GR homodimer binding to GRE consensus
elements, ligand-bound GR may translocate to the nucleus and bind to other transcription factors,
such as AP-1 and KF-κB, and interfere with their ability to function as transcription factors (20).
GR activation of catabolic pathways including the ubiquitin proteasome system and autophagy
pathways are thought to play a major role in the molecular mechanisms responsible for skeletal
muscle atrophy resulting from increased glucocorticoid exposure (18). In fact, both MuRF1 and
MAFbx contain glucocorticoid response elements that enhance their expression in the presence
of GCs (17,18)
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Figure 7. Glucocorticoid receptor (GR) signaling. Following glucocorticoid binding, GR
becomes phosphorylated and translocates to the nucleus where it may influence transcription of
target genes in a multitude of ways (20).

10

Chapter 2: Identification and Functional Analysis of Family with sequence similarity 83 D
(Fam83d) in Skeletal Muscle

Introduction
Overview of Fam83d
Fam83d is one of 8 members of a family of proteins related by a highly conserved domain of
unknown function, DUF1669, found at the N-terminus of each protein (21). This group of
proteins shares little homology outside of the DUF1669 region. Endogenous expression of this
family of proteins varies across tissue types but all members have been shown to be upregulated
in one or more tumor types (21). Indeed, several studies have examined the function of Fam83d
in cancer, including its role in breast cancer (22, 23), hepatocellular carcinoma (24) (25) lung
cancer (26, 27) ovarian cancer (28, 29) and colorectal cancer (30). While its precise role in
oncogenesis remains unclear, previous studies have demonstrated its involvement in several cell
signaling pathways involved in cell proliferation and differentiation, including the MAP kinase,
AKT/mTOR, and Wnt/β-catenin signaling cascades (22, 23, 24, 25, 26, 27, 28, 29, 30).
Materials and Methods
Cell Culture

The C2C12 immortalized mouse myoblast cell line was obtained from the American Type Culture
Collection (Manassas, VA) and maintained in DMEM (Life 163 Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS) (GE164 Healthcare HyClone
Laboratories, Logan, UT), non-essential amino acids, gentamicin, penicillin and streptomycin
(all from Life Technologies, Grand Island, NY). Cells were grown in a humidified chamber at
37⁰C at 5% CO2. Cells were switched to DMEM supplemented with 2% FBS, non-essential
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amino acids, gentamicin, penicillin and streptomycin 48 hours post plating to stimulated
myotubes differentiation.

RNA Isolation and cDNA synthesis
Total RNA was isolated from C2C12 myoblast cells using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer's protocol. Purified RNA (1µg) was reversetranscribed using Oligo-dT primers and Moloney Murine Leukemia Virus (M-MLV) Reverse
Transcriptase according to the manufacturer's protocol (Life Technologies, Grand Island, NY)

Amplification and cloning of the full length Fam83d cDNA
For the amplification of Fam83d cDNA, gene-specific primer pairs were designed (Table 1)
using the gene sequences from Mus musculus (GenBank accession number: NM_027975). PCR
was performed according to the manufacturer's protocol (Life Technologies, Grand Island, NY)
using Taq DNA polymerase, template prepared by reverse transcription of RNA isolated from
C2C12 cells as described above and gene specific primer pairs (Table 1). Amplicons were cloned
into the pGEM-T Easy vector (Promega, Madison, WI) according the manufacturer's protocol
and sequenced using the Big Dye Sanger terminator sequencing method (Eurofins MWG
Operon, Huntsville, AL) to confirm amplification of the expected target and the absence of
mutations. The Fam83d cDNA was sub-cloned into the Xho1 and Xba1 restriction sites of
pcDNA3.1 (+) (Life Technologies, Grand Island, NY) and sequenced to confirm correct
orientation. The Fam83d cDNA was also sub-cloned into the Xho1 and Xba1 restriction sites of
the pEGFP-C3 expression plasmid (Clontech, Mountain View, CA) and sequenced to confirm
correct orientation and in frame fusion with GFP. The Fam83d cDNA fused to myc and DDDDK
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tags in the PS100001 vector was purchased from OriGene Technologies (Rockville, MD) catalog
number MR209141.

Promoter cloning of the Fam83d gene
For the amplification of the proximal regulatory region of Fam83d, genomic DNA was isolated
from C2C12 cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according to
the manufacturer's protocol. PCR was performed using Fam83d promoter region-specific primer
pairs (Table 1) developed using mouse genomic sequences obtained from the Ensembl database
(www.ensembl.org). PCR reactions were performed using Taq DNA polymerase and genomic
mouse DNA according to the manufacturer's protocol (Life Technologies, Grand Island, NY).
The PCR amplicons were cloned into the pGEM-T Easy vector (Promega, Madison, WI)
according to the manufacturer's protocol and sequenced to confirm amplification of the predicted
target region and the absence of mutations. The Fam83d promoter fragments (~500 and ~1000
base pairs) were sub-cloned into the HindIII and Xho I sites of the pSEAP2-Basic reporter
plasmid (Clontech, Mountain View, CA) to create the pSEAP-Fam83d-Pro500 and the pSEAPFam83d-Pro1000 reporter plasmids and sequenced to confirm correct orientation.

Site-directed mutagenesis
The putative phospholipase D-like catalytic domain sequence located in exon 3 of Fam83d was
mutated (H239N and K241Q) using the primer pairs listed in Table 1. The Fam83d-F280A
mutant was generated using the primers listed in Table 1. The QuikChange II Site Directed
Mutagenesis protocol utilizing PfuTurbo DNA polymerase was performed according to the
manufacturer's protocol (Agilent Technologies, Santa Clara, CA). The mutagenesis PCR
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reactions were digested with DpnI (New England BioLabs, Ipswich, MA) and then transformed
into heat competent DH5α E.coli cells (Life Technologies, Grand Island, NY). Clones were
isolated and plasmids were purified via alcohol precipitation and sequenced to confirm
successful mutation of the phospholipase D-like domain catalytic pocket.

Transfections
C2C12 myoblast cells were plated into 12 well plates at a density of 75,000 cells/well with
DMEM + 10% FBS (proliferation media) and cultured overnight. All conditions assessed were
conducted in triplicate. Transfections were performed utilizing Turbofect Transfection Reagent
(Thermo Scientific, Rockford, IL) following manufacturer protocol. One hour prior to
transfection, media was refreshed and 1 μg of total DNA (250 ng/well of reporter plasmid, 125
ng/well of β -galactosidase (β-gal) as the internal control plasmid, and empty pBluescript vector
as filler DNA to 1 μg DNA/well) was allowed to complex with transfection reagent for 20
minutes prior to overlaying the cells. Following 24-hour incubation with the transfection
reaction, the proliferation media was replaced with differentiation media (DMEM + 2% FBS)
and incubated for an additional 24-72 hours until reporter assays were performed.

Reporter gene assay
Growth media was collected from C2C12 mouse myoblasts at 24–72 hr after the switch to
differentiation media post transfection and tested for SEAP levels using the Phospha‐Light SEAP
Reporter Gene Assay Kit and following the manufacturer’s instructions (Life Technologies,
Grand Island, NY). The level of SEAP generated luminescence was assessed with a Synergy 2
microplate reader programmed for an endpoint read and a 2 s integration time. At the conclusion
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of the experiment, cells were lysed with Passive Lysis Buffer (Promega, Madison, WI), lysates
were centrifuged to clear cell debris and assessed for β‐galactosidase (β‐gal) activity. The SEAP
activity numbers were corrected with β‐gal activity numbers to adjust for any variation in
transfection levels between wells.

Bioinformatic analysis of Fam83d
DNA sequences corresponding to the promoter regions of human, rat, and mouse Fam83d
(Ensembl Transcript ID: ENST00000619850.2, ENSRNOT00000021308.4, and
ENSMUST00000029183.2, respectively) starting at ‐2000 and including the first exon were
taken from the Ensembl database (www.ensembl.org) and analyzed using the Clustal Omega
multiple sequence alignment tool available on the EMBL‐EBI website
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The Clustal Omega alignment data was then
analyzed using Boxshade version 3.21 (http://www.ch.embnet.org/software/BOX_form.html)
that is available on the ExPASy (www.expasy.org) website. The polypeptide sequences for
human, mouse, and rat Fam83d were also downloaded from Ensembl and aligned using the
Clustal Omega alignment tool and shaded with Boxshade as described for the promoter
sequences above.

Quantitative PCR
Total RNA was isolated from proliferating and differentiated C2C12 cells as described above.
Purified total RNA (1.0 μg) was reverse‐transcribed using the iScript cDNA Synthesis Kit
according to the manufacturer’s protocol (Bio‐ Rad, Hercules, CA). cDNA amplification was
conducted using the iTaq Universal SYBR Green Reaction Supermix and gene specific primers
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(Table 1) according to the manufacturer’s protocol (Bio‐Rad, Hercules, CA) and the CFX
Connect Real‐Time PCR Detection System (Bio‐Rad, Hercules, CA) was used to analyze
quantitative gene expression of Fam83d at PD2, DD2 and DD7. Each timepoint was performed
in biological triplicates, each individual biological replicate was used for cDNA synthesis in
duplicate, and each cDNA synthesis replicate plated and analyzed in technical triplicates (three
biological replicates × two cDNA synthesis replicates × three technical replicates = 18 individual
reads per biological sample) and the experiment was repeated at least twice. Relative gene
expression was calculated using the 2−ΔΔCt Livak method and GAPDH as the reference gene.

Protein purification and Western blot analysis
C2C12 cells were cultured in 10 cm culture dishes and Fam83d was exogenously expressed by
transfecting the cells with the PS100001‐Fam83d-myc-DDK or pcDNA3.1-Fam83d expression
plasmid 24 h post‐plating. The Fam83d overexpression time course was collected by harvesting
cells 48 h post‐plating (PD2), as well as cells cultured for an additional 1,3 or 5 days in
differentiation media (DD1, DD3, DD5). The collected cells were spun down and kept at −80°C
until cell homogenization and protein isolation was performed.

The harvested cells were incubated on ice for 30 min, with agitation every 10 minutes, in
Universal Lysis Buffer (50mM Tris, pH 7.5, 150mM NaCl, 50mM NaF, 0.5% NP‐40), plus
additions (1mM PMSF, 1mM DTT, 10mM β-glycerophosphate, 2mM sodium molbydate, and a
protease inhibitor cocktail; ULB(+)). Cell homogenates were centrifuged to clear cellular debris
and protein concentrations were determined using the Quick Start Bradford 1× Dye Reagent
(Bio‐Rad, Hercules, CA) following the manufacturer’s instructions.
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Western blots were conducted using 75-100 μg of protein on a 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis denaturing gel and then transferring overnight to
polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA). Membranes were stained
with Ponceau S to visualize equal protein loading and successful transfer and then incubated with
blocking solution (5% w/v dry milk in tris‐buffered saline with 0.05% Tween‐20). Western blots
were probed with anti-Fam83d (gift from Dr. Gopal Sapkota, University of Dundee, United
Kingdom), anti-myosin heavy chain (MYH1/2/4/6; sc-32732; Santa Cruz Biotechnology Dallas,
TX), anti-myogenin (F5D; sc-12732; Santa Cruz Biotechnology, Dallas, TX), anti-p-ERK (E4;
sc-7383; Santa Cruz Biotechnology, Dallas, TX), anti-ERK1 (K-23; sc-94; Santa Cruz
Biotechnology, Dallas, TX), anti-Fbxw7 (28424-1-AP; ProteinTech, Rosemont, IL), antiCSNK1α1 (55192-1-AP; ProteinTech, Rosemont, IL), anti-MEK1/2 (11049-1-AP; ProteinTech,
Rosemont, IL), anti- Calcoco1 (19843-1-AP; ProteinTech, Rosemont, IL), anti-HMMR (158201-AP; ProteinTech, Rosemont, IL), anti-AKT-phospho-S473 (66444-1-lg; ProteinTech,
Rosemont, IL). Anti-AKT (60203-2-lg; ProteinTech, Rosemont, IL), anti-phospho-mTORSer2448 (D9C2; #5536; Cell Signaling Technology, Danvers, MA), anti-phosphomTORSer2481 (#2974; Cell Signaling Technology, Danvers, MA), antiphospho-MEK1/2
(9154T; Cell Signaling Technology, Danvers, MA), anti-phospho-GSK-3β (5558 T; Cell
Signaling Technology, Danvers, MA), anti- GSK-3β (22104–1-AP; ProteinTech, Rosemont, IL),
antimTOR (66888–1-lg; ProteinTech, Rosemont, IL) anti-myc (60003–2-lg; ProteinTech,
Rosemont, IL), anti-DDDDK (FLAG equivalent) (20543–1- AP; ProteinTech, Rosemont, IL)
anti-GAPDH (60004–1-lg; ProteinTech, Rosemont, IL) and anti-α tubulin (DM1A; sc-32293;
Santa Cruz Biotechnology, Dallas, TX) primary antibodies followed by probing with an
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appropriate HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) (Table
2). Western blots were visualized using ECL substrate according to the manufacturer's
instructions (Pierce/Thermo Fisher Scientific, Rockford, IL). PVDF membranes were stripped by
incubating for 20–30 min in stripping buffer (10%SDS, 0.5 M tris-HCl pH 6.8 and βmercaptoethanol) at 50 °C, and then blocked, re-probed, and visualized as described above.
Western blot band intensity quantifications were conducted using the open access ImageJ
software.

Confocal Fluorescence Microscopy
C2C12 cells were plated using Cellvis (Sunnyvale, CA) 35mm glass bottom dishes and
transfected 24 h after cells were plated with either the pEGFP‐C3 or pEGFP‐Fam83d plasmids
duplexed with TurboFect Reagent (Thermo Fisher Scientific, Rockford, IL) as per
manufacturer’s instructions. Before imaging, the cells were washed with phosphate buffered
saline, fixed with paraformaldehyde, dissolved in sodium cacodylate, and stained with DRAQ5
fluorescent DNA dye (Biostatus, Leicestershire, UK). The images were acquired using an
Olympus Fluoview FV‐1000 confocal fluorescent microscope equipped with Super Apochromat
UPLSAPO 20X and Super Apochromat UPLSAPO 60XW objectives. Open access ImageJ
software combined with the Open Microscopy Environment Bio‐Formats plugin was used to
analyze, merge, and save all images.

Co-immunoprecipitation
C2C12 cells were grown in 10% FBS DMEM media and transfected with Fam83d-myc-DDK
expression plasmid and harvested 24 hours post transfection. Cells were lysed on ice for 30

18

minutes in ULB(+) (50mM Tris, pH 7.5, 150mM NaCl, 50mM NaF, 0.5% NP-40, 1mM PMSF,
1mM DTT, 10mM β-glycerophosphate, 2mM sodium molbydate and a protease inhibitor
cocktail). Protein was isolated by centrifugation and protein concentrations were quantified using
the Quick Start Bradford 1X Dye Reagent (Bio-Rad, Hercules, CA) according to the
manufacturer’s protocol. 500μg protein was diluted in ULB and precleared with protein A/G
agarose beads (Pierce/Thermo Scientific, Rockford, IL) for 1 hour at 4°C with constant endover-end rotation. Beads were cleared from solution via centrifugation and the supernatant was
incubated with 2μg anti-myc (60003-2-lg; Proteintech, 318 Rosemont, IL) antibody for 4 hours
at 4°C with constant end-over-end rotation. Protein A/G agarose beads were added to solution
and incubation was continued for 6 additional hours. Beads were cleared from solution via
centrifugation and pelleted beads were washed 3X with ULB, and then boiled for 5 mins at
95°C. 50μg of protein lysate was used for input control and SDS-PAGE was performed.
Separated proteins were then transferred to a PVDF membrane and probed using the antibodies
described above.

Statistics
Data are presented as the mean ± standard deviation (SD). Statistical analysis was conducted
using a two-tailed t-test and a difference was considered statistically significant at a P value <
0.05.
Table 1. List of primers used in the Fam83d study
Primer
Sequence (5’-3’)
Fam83d-cDNA-F
GCAAGCTTGCCATGGCTGCTCGCTTCGAGC
Fam83d-cDNA-R
GCGAATTCCGGCAGTCACTGATAGGGAGGG
Fam83d-cDNA-Mut-F
CGGGAAGGTTAATGAGCAGTTCACACTG
Fam83d-cDNA-Mut-R
CAGTGTGAACTGCTCATTAACCTTCCCG
Fam83d-pro500-F
GCCTCGAGGATGCAGGGTGGAGTGGCAATGAGGC
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Fam83d-pro1000-F
Fam83d-pro5000-R
Fam83d-qpcr-F
Fam83d-qpc-R

GCCTCGAGCCTCCCATGTGCTGGGAGTGTGCCACC
GCAAGCTTGCCCAGAACCGATCCACTTGTCTACG
GATCTGAGAGTTCATCCTGAGC
CAACCTTTGTTCCTGACCTTGC

Table 2. List of antibodies used in the Fam83d study
Antibody
Source
anti-Fam83d
University of Dundee, Scotland
anti-Calcoco1
ProteinTech, Rosemont, IL
anti-myc
ProteinTech, Rosemont, IL
anti-α-tubulin
anti-Myosin Heavy
Chain (MYH1/2/4/6)
anti-myogenin
anti-GAPDH
anti-phospho-ERK
anti-ERK
anti-phospho-MEK1/2
(Ser217/221)
anti-MEK1/2
anti-Akt1-phosphoS473
anti-Akt
anti-phospho-mTORSer2448
anti-mTOR
anti-phospho-GSK3β
(Ser9)
anti-GSK3β
anti-CSNK1A1
anti-FBXW7
anti-HHMR
anti-DDK
Mouse anti-rabbit IgGHRP
Rabbit anti-mouse IgGHRP (H+L)
Donkey anti-Sheep
IgG-HRP (H+L)
Goat anti-mouse IgG
(H+L), FITC conjugate

Catalog #

Santa Cruz Biotechnology, Dallas, TX
Santa Cruz Biotechnology, Dallas, TX

sc-32293
sc-32732

Dilution
WB: 1:500
WB: 1:2000
WB: 1:2000
IF: 1:50
WB: 1:1000
WB: 1:1000

Santa Cruz Biotechnology, Dallas, TX
ProteinTech, Rosemont, IL
Santa Cruz Biotechnology, Dallas, TX
Santa Cruz Biotechnology, Dallas, TX
Cell Signaling Technology, Danvers, MA

sc-12732
60004-1-lg
sc-7383
sc-94
9154

WB: 1:1000
WB: 1:5000
WB: 1:1000
WB: 1:1000
WB: 1:2000

ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL

11049-1-AP
66444-I-lg

WB: 1:5000
WB: 1:2000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

60203-2-lg
5536

WB: 1:5000
WB: 1:2000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

66888-1-lg
5558

WB: 1:10000
WB: 1:1000

ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL
Santa Cruz Biotechnology, Dallas, TX

22104-1-AP
55192-1-AP
28424-1-AP
15820-1-AP
20543-1-AP
sc-2357

WB: 1:2000
WB: 1:2000
WB: 1:5000
WB: 1:1000
WB: 1:5000
WB: 1:5000

Thermo Scientific, Rockford, IL

PI31450

WB: 1:5000

Jackson Immuno Research, West Grove,
PA
ProteinTech, Rosemont, IL

713-035147
SA00003-1

WB: 1:10000

19843-1-AP
60003-2-lg

IF: 1:100
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Results
Fam83d is upregulated during neurogenic skeletal muscle atrophy
RNA was isolated from control and denervated mouse gastrocnemius and soleus muscles and an
Illumina mouse-6 v1.1 microarray was performed at 3 days and 14 days post denervation as
previously described (5). Analysis of the microarray data submitted to the NCBI Gene
Expression Omnibus (GEO) revealed a significant number of genes that show differential
expression patterns in response to neurogenic muscle atrophy (5). Many of these genes have not
previously been implicated in atrophy and have not been characterized in skeletal muscle.
Fam83d shows low basal levels of expression in control gastrocnemius and soleus muscles and
there was no significant difference in expression between control and denervated tissue at 3 days
post-denervation; however, Fam83d was shown to be significantly upregulated by day 14 postdenervation compared to control muscles (Fig. 8A). Fam83d is found on chromosome 2 in mice
and is composed of four exons and three introns (Fig. 8B). The Fam83d gene locus shows
architectural conservation between mouse and human and lies immediately downstream of
Ppp1r16b and immediately upstream of Dhx35 in both species (Fig. 8C).
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Figure 8. Fam83d is upregulated during neurogenic atrophy. (A) Whole genome expression
analysis was conducted on triceps surae muscle from wild-type (WT) mice after 3 days (3D) and
14 days (14D) of denervation. Each condition represents the average expression from three
animals and error bars represent ± SD. White bars, controls (Con); black bars, denervated (Den).
Significant difference between denervated mice and control mice in the same group (**:P < .01).
(B) Schematic of the Fam83d transcript in mouse. Darkened rectangles represent the exons
containing the translated region, open rectangles represent exons containing the untranslated
regions, and the lines connecting these rectangles represent introns. (C) Schematic of the mouse
and human Fam83d gene loci on Chromosomes 2 and 20, respectively and the relative positions
of adjacent genes.

Fam83d is expressed during muscle cell proliferation but is rapidly degraded as cells
differentiate
To measure the transcriptional activity of Fam83d, total RNA was harvested from C2C12 mouse
myoblasts during proliferation (PD2), as well as, from myotubes at early (DD2) and late (DD7)
differentiation timepoints. cDNA synthesized from isolated RNA was used to conduct RT-qPCR
using Fam83d specific primers (Table 1). The qPCR analysis demonstrated that Fam83d mRNA
levels are significantly higher during proliferation when compared to both early and late
differentiation timepoints (Fig. 9A). To validate the ability of a Fam83d antibody, generously
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provided by Dr. Gopal Sapkota at the University of Dundee, United Kingdom, to detect mouse
Fam83d, NIH3T3 cells were transfected with either a pcDNA3-Fam83d or pEGFP-Fam83d
expression plasmid. Protein homogenates isolated from control cells and transfected cells were
then analyzed by Western blot and the Fam83d antibody was able to successfully detect both the
untagged and GFP-tagged Fam83d proteins (Fig. 9B). Protein homogenates from C2C12 cells
isolated from proliferating myoblasts (PD2) and cells differentiated for 1, 3, and 5 days were
analyzed by Western blot using the validated anti-Fam83d antibody to assess endogenous
Fam83d protein levels. In agreement with the qPCR data, Western blot analysis revealed that
Fam83d protein levels are higher during proliferation and then rapidly decrease as muscle cells
differentiate (Fig. 9C). Myosin Heavy Chain (MyHC) was analyzed as a marker of muscle cell
differentiation, Calcoco1 was used as a control for protein stability during differentiation, and αtubulin was used as a loading control.

To determine if this decrease in protein level was due to degradation through the 26S proteasome
pathway, C2C12 cells were transfected with a Fam83d-myc expression plasmid and treated with
increasing concentrations of the proteasome inhibitor MG132. Cells were harvested 12 h postMG132 treatment and protein lysates were analyzed by Western blot. The levels of myc-tagged
Fam83d were found to be much higher at differentiation day one compared to DMSO treated
control cells (Fig. 9D).
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Figure 9. Fam83d expression in mouse myoblasts. (A) Fam83d mRNA is expressed highly
during proliferation and then decreases significantly during differentiation. Quantitative
polymerase chain reaction (qPCR) utilizing cDNA generated from RNA isolated from C2C12
cells harvested at proliferation day 2 (PD2), differentiation day 2 (DD2) and differentiation day 7
(DD7). Cells were maintained in proliferation media (10% serum) and harvested at 2 days postplating and the remaining cells were switched to differentiation media (2% serum) and harvested
at 2- and 7-days post-media change. Significant difference between Fam83d expression in
differentiated cells compared to Fam83d expression in proliferating cells (*:P < .05, **:P < .01).
(B) Validation of a Fam83d antibody to detect murine Fam83d using protein lysates from
NIH3T3 cells ectopically expressing mouse Fam83d. NIH3T3 cells were transiently transfected
with pcDNA3-Fam83d, or pEGFP-Fam83d and 25 μg, 50 μg or 75 μg of protein lysate was
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loaded and analyzed by Western blot. (C) Western blot analysis was performed with the
validated Fam83d antibody using protein homogenates from proliferating [P] and differentiated
[D] C2C12 cells harvested over a 5-day differentiation time course to assess endogenous Fam83d
protein levels. Cells were maintained in proliferation media (10% serum) and harvested at 2-days
post-plating and the remaining cells were then switched to differentiation media (2% serum) and
harvested at 1, 3, and 5 days post-media change. Myosin Heavy Chain (MyHC) was analyzed as
a marker of differentiation, Calcoco1 was analyzed as a protein that is not affected by muscle
cell differentiation, and α-tubulin was analyzed to confirm equal protein loading. (D) Western
blot analysis using lysates from C2C12 cells transfected with a Fam8d3-myc-Flag expression
plasmid, treated with MG132 (0.625, 1.25, and 2.5 μM), harvested after 1 day of differentiation,
and probed using an anti-myc antibody. α-tubulin was analyzed to confirm equal protein loading.
Fam83d Expression Is Regulated by Myogenic Regulatory Factors
To gain insight into how Fam83d is regulated transcriptionally in muscle cells, 416 and 785 base
pairs of the promoter were amplified using the primers listed in Table 1. The fragments were
then fused to a secreted alkaline phosphatase (SEAP) reporter plasmid to create the pSEAPFam83d-Pro416 and pSEAP-Fam83d-Pro785 reporter constructs. The Fam83d reporter gene
constructs were transfected into C2C12 mouse myoblasts and SEAP assays were performed 48 h
after the switch to differentiation media. The 416 and 785 bp fragments both showed
significantly higher expression compared to the empty plasmid alone (Fig. 10A). Bioinformatic
analysis of the promoter region of Fam83d revealed three canonical E-Box elements within the
first 400 bps upstream of the start of transcription (Fig. 10B). Myogenic regulatory factors, such
as MyoD, are known to regulate gene transcription through interaction with E-box consensus
elements (5′- CANNTG-3′) found in the promotors of muscle-specific genes. Therefore, to
determine if the Fam83d reporter genes are responsive to ectopic expression of MyoD, cells were
transfected with a MyoD expression plasmid in combination with the reporter gene constructs.
Overexpression of MyoD significantly repressed the transcriptional activity of both the pSEAPFam83d-Pro416 and pSEAP-Fam83d-Pro785 reporter constructs (Fig. 10C and D).
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Figure 10. Cloning and analysis of the proximal regulatory region of the Fam83d gene locus.
(A) C2C12 myoblasts were transfected with either an empty reporter plasmid or reporter plasmids
containing 416 bp or 785 bp of the Fam83d promoter fused to the Secreted Alkaline Phosphatase
(SEAP) reporter gene. Each condition was performed in triplicate and each experiment was
repeated at least three times (n = 3). The graphs are of a representative experiment and values
correspond to the mean relative light unit (RLU) values ±SD. Significant difference between the
empty control reporter plasmid (pSEAP2-Basic) and the pSEAP2-Fam83d reporter constructs,
(*: P < .0001). (B) Schematic and sequence alignment of the Fam83d regulatory region.
Promoter sequences from mouse, rat, and human Fam83d (2000 base pairs upstream of the
transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Approximate positions of
putative transcription factor binding sites are indicated in the schematic of the Fam83d
regulatory region at the top. Putative TFIIB Response Element (BRE) 5′(G/C)(G/C(G/A)CGCC-3′ (black trapezoids) and putative consensus E-box elements 5′CANNTG-3′ (checkered diamond and dotted triangle) are indicated. N represents any nucleotide.
Conserved nucleotides are highlighted in black, transitions are highlighted in gray, and
transversions are highlighted in white. C2C12 myoblasts were transfected with either the (C)
pSEAP2-Fam83d-Pro416 reporter or the (D) pSEAP2-Fam83d-Pro785 reporter with or without a
MyoD expression plasmid. The media was then assayed for SEAP activity 48 h (DD2) following
the switch to differentiation media and SEAP numbers were normalized to β-galactosidase
activity to correct for variations in transfection efficiency. Each condition was performed in
triplicate and each experiment was repeated at least three times (n = 3). The graphs are of a
representative experiment and values correspond to the mean relative light unit (RLU) values
±SD. Significant differences between the activities of the pSEAP2-Fam83d-Pro reporter
constructs with and without MyoD ectopic expression, (**: P < .01).
Subcellular localization of Fam83d
The Fam83d gene is located on chromosome 2 in mouse and encodes a 585 amino acid
polypeptide with a predicted molecular weight of approximately 56 kDa, although the observed
molecular weight appears closer to 70 kDa (Fig. 9C). The Fam83d protein contains a
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putative domain of unknown function (DUF) located at the N-terminus of the polypeptide
(highlighted in red in the alignment), which is conserved among all members of the Fam83
family (Fig. 11A). Further analysis utilizing the NCBI conserved domain database identified a
putative phospholipase D-like (PLD-like) catalytic motif (highlighted in green in the alignment)
within this DUF region (Fig. 11A). As this is the first study to describe Fam83d in skeletal
muscle, there are no other reports describing its localization in muscle cells. Therefore, Fam83d
was fused with GFP and the fusion protein was ectopically expressed in cultured myoblasts to
determine subcellular localization by confocal fluorescent microscopy. C2C12 cells were
transfected with either an empty GFP expression plasmid or a Fam83d-GFP expression plasmid
and analyzed 24 h post-transfection. The control cells transfected with the empty GFP expression
plasmid showed uniform GFP localization throughout the cell (Fig. 11B, Panels 1–3), while cells
transfected with the Fam83d-GFP fusion plasmid showed accumulation in puncta located in the
cytoplasm of cultured myoblasts (Fig. 11B, Panels 4–12). Since GFP has been known to affect
localization of proteins it is fused with, we also overexpressed myc-tagged Fam83d in C2C12
myoblasts and performed immunofluorescence using an anti-myc antibody and a FITCconjugated secondary and found that the localization pattern matched the GFP-Fam83d
localization pattern (Fig. 11C)

28

29

30

Figure 11. Fam83d localizes to the cytoplasm of myoblast cells. (A) Sequences of the mouse,
rat, and human Fam83d protein were downloaded from the Ensembl database and aligned using
the ClustalW2 algorithm. Approximate position of the domain of unknown function 1669
(DUF1669) is highlighted in red and the putative phospholipase D-like motif catalytic pocket is
highlighted in greed in the alignment. (B) Proliferating C2C12 cells (PD2) transfected with the
empty pEGFP-C3 expression vector were imaged at 20× (Panels 1–3) and uniform cellular
localization of GFP was observed. Representative C2C12 cells transfected with a pEGFP-Fam83d
expression plasmid were imaged at proliferation day 2 (PD2) at 20× (Panels 4–6), 60× (Panels
7–9, and 100× (Panels 10–12) and punctate cytoplasmic fluorescence was observed. Draq5, a
cell permeable fluorescent DNA dye, was used to visualize cell nuclei. (C) Immunofluorescent
detection of Fam83d-myc-Flag was performed using C2C12 myoblast cells. C2C12 cells were
transfected with a Fam83d-myc-Flag expression plasmid and then incubated with a myc primary
antibody and a FITC-conjugated secondary antibody revealing punctate cytoplasmic
fluorescence at 60× (Panels 1–3) and 100× (Panels 4–9) magnification. Draq5, a cell permeable
fluorescent DNA dye, was used to visualize cell nuclei and merged images were generated using
ImageJ.
Ectopic expression of Fam83d inhibits muscle cell differentiation
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To evaluate if Fam83d impacts muscle cell differentiation, C2C12 cells were transfected with a
myc-tagged Fam83d expression plasmid. Cells were then harvested over a time course that
included 2 days of proliferation (PD2) and 1, 3 and 5 days of differentiation (DD1, DD3
and DD5, respectively). Protein was isolated from cells and evaluated for the level of expression
of the canonical makers of muscle cell differentiation, skeletal muscle myosin heavy chain
(MyHC) and myogenin. Western blot analysis showed significantly lower levels of both
myogenin and MyHC at all differentiation time points (Fig. 12A). To quantify the amount of
inhibition, Fam83d was overexpressed in biological quadruplicates and harvested at 3 days of
differentiation. Lysates were evaluated by Western blot and myogenin and MyHC expression
levels and were found to be significantly repressed in lysates isolated from cells ectopically
expressing Fam83d (Fig. 12B and C). Fam83d protein levels were analyzed to confirm
overexpression and GAPDH was analyzed to confirm equal loading and to correct for variations
in protein levels between individual lanes (Fig. 12A and B).
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Figure 12. Ectopic expression of Fam83d attenuates muscle cell differentiation. C2C12 cells were
transfected with a Fam83d-myc-Flag expression plasmid or mock transfected followed by
Western blot analysis. (A) Western blot analysis of Fam83d, Myosin Heavy Chain (MyHC), and
myogenin using protein homogenates from proliferating (PD) and differentiated (DD) C2C12
cells harvested over a 5-day differentiation time course. Cells were maintained in proliferation
media (10% serum) and harvested 2 days post-plating and the remaining cells were then
switched to differentiation media (2% serum) and harvested at 1, 3 and 5-days post-media
change. GAPDH was analyzed to confirm equal protein loading. The experiments were repeated
at least three times and the Western blots shown are representative examples of the results
obtained. (B) C2C12 cells were transfected with a Fam83d-myc-Flag expression plasmid or mock
transfected in biological quadruplicates and cell lysates were then analyzed by Western blot for
Fam83d, MyHC, and myogenin. Cells were maintained in proliferation media then switched to
differentiation media (2% serum) for 3 days. GAPDH and α-tubulin was analyzed to confirm
equal protein loading. The experiment was performed in quadruplicate (n = 4), repeated at least
three times, and the blots shown are representative examples of the results obtained. (C)
Quantification of the Western blot band intensities for Fam83d, MyHC, and myogenin. Relative
intensity of each band was corrected to either GAPDH (shown) or α-tubulin band intensities for
each corresponding biological replicate. Significant differences between control cells compared
to cells ectopically expressing Fam83d-myc-Flag, (****: P < .0001).
Fam83d overexpression attenuates MAP kinase signaling
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To determine if Fam83d overexpression impacts MAP kinase signaling, C2C12 cells were
transfected with a pSEAP-Pro-AP-1 reporter construct in combination with increasing
concentrations of a wild-type Fam83d-myc-Flag expression plasmid (Fam83d-myc-Flag WT).
Growth media was sampled 24 h post-transfection to evaluate SEAP levels in proliferating
myoblasts and the AP-1 reporter showed significant activity at this timepoint in control cells,
while Fam83d overexpression significantly reduced reporter activity in a dose-dependent manner
(Fig. 13A). To confirm that Fam83d ectopic expression negatively regulates the MAP kinase
signaling pathway, C2C12 mouse cells were harvested over a differentiation time course, as well
as, in biological quadruplicate at differentiation day 3 (DD3) as described above. Protein
homogenates from cells ectopically expressing Fam83d were evaluated by Western blot to assess
the effect that overexpression has on MAP kinase signaling. ERK1/2 phosphorylation levels
decreased significantly in lysates isolated from cells overexpressing Fam83d at all differentiation
time points assessed (Fig. 13B-D). To determine if Fam83d functions upstream of ERK1/2 in the
MAP kinase signaling cascade, MEK1/2 and phosphorylated MEK1/2 levels were also evaluated
by Western blot. Overexpression of Fam83d did not significant effect the level of whole
MEK1/2 protein, but did show a small but significant inhibition of the phosphorylation status of
MEK1/2 (p- MEK), suggesting that Fam83d likely influences MAP kinase signaling
predominantly at the level of ERK1/2 in muscle cells (Fig. 13B-D). To investigate if a putative
phospholipase D-like (PLD-like) motif is necessary for Fam83d inhibition of MAP kinase
signaling, site-directed mutagenesis was used to modify two residues in the predicted catalytic
pocket to create the Fam83d-H239N/K241Q double mutant. Interestingly, in contrast to wildtype Fam83d, overexpression of the Fam83d PLD-like motif mutant did not significantly inhibit
the AP-1 reporter activity (Fig. 13A). To confirm that Fam83d-H293N/K241Q ectopic
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expression does not negatively regulate the MAP kinase signaling pathway to the same level as
wild-type Fam83d, C2C12 cells were harvested in biological quadruplicate at DD3. Western blot
analysis showed that overexpression of the Fam83d phospholipase D-like motif mutant had no
significant effect on ERK1/2 protein or phosphorylation levels, in contrast to wild-type Fam83d
(Fig. 13E and F).
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Figure 13. Fam83d overexpression inhibits AP-1 reporter activity and MAP kinase signaling.
(A) C2C12 cells were transfected with an AP-1 reporter plasmid and either a wild-type Fam83d or
Fam83d-H239N/K241Q double mutant expression plasmid. The media was then assayed for
SEAP activity 48 h (DD2) following the switch to differentiation media and SEAP numbers were
normalized to β-galactosidase activity to correct for variations in transfection efficiency. Each
condition was performed in triplicate and each experiment was repeated at least three times (n =
3). The graphs are of a representative experiment and values correspond to the mean relative
light unit (RLU) values ±SD. Significant differences between the activities of the pSEAP2-AP-1Pro reporter construct alone and in combination with Fam83d-WT or Fam83d-H239N/K241Q
ectopic expression, (**: P < .01, ***: P < .001). (B) C2C12 cells were transfected with a Fam83dmyc-Flag expression plasmid or mock transfected followed by Western blot analysis. Cells were
maintained in proliferation media (10% serum) and harvested 2 days post-plating and the
remaining cells were then switched to differentiation media (2% serum) and harvested 1, 3, and 5
days post-media change. Western blot analysis of phosphorylated-ERK1/2 (p-ERK1/2), panERK1/2 (ERK1/2), phosphorylated-MEK1/2 (p-MEK1/2), and pan-MEK1/2 (MEK1/2) using
protein homogenates from proliferating (PD2) and differentiated C2C12 cells. The experiments
were repeated at least three times (n = 3) and the Western blots shown are representative
examples of the results obtained. (C) C2C12 cells were transfected with a Fam83d-myc-Flag WT
expression plasmid or mock transfected in biological quadruplicates. Western blot analysis of
phosphorylated ERK1/2 (p-ERK1/2), pan-ERK1/2 (ERK1/2), phosphorylated-MEK1/2 (pMEK1/2), and pan-MEK1/2 (MEK1/2) using protein homogenates from C2C12 cells
differentiated for 3 days. The experiment was performed in quadruplicate (n = 4), repeated at
least three times, and the blots shown are representative examples of the results obtained. (D)
Quantification of the Western blot band intensities were measured for pan-ERK1/2 and panMEK1/2 protein levels, as well as, the phospho-ERK1/2 to pan-ERK1/2 ratio and the phosphoMEK1/2 to pan-MEK ratios. Significant differences between control cells compared to cells
ectopically expressing Fam83d, (*: P < .05, **: P < .01, N.S. = not significant). (E) C2C12 cells
were transfected with a Fam83d-H239N/K241Q expression plasmid or mock transfected in
biological quadruplicates. Western blot analysis of Fam83d, phosphorylated-ERK1/2 (pERK1/2), pan-ERK1/2 (ERK1/2), phosphorylated-MEK1/2 (p- MEK1/2), and pan-MEK1/2
(MEK1/2) using protein homogenates from C2C12 cells differentiated for 3 days. The experiment
was performed in quadruplicate (n=4), repeated at least three times, and the blots shown are
representative examples of the results obtained. (F) Quantification of the Western blot band
intensities were measured for pan-ERK1/2 and the phospho-ERK1/2 to pan-ERK1/2 ratio. (N.S.
= not significant).
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Fam83d overexpression attenuates AKT signaling
The effect of Fam83d overexpression on AKT signaling was also evaluated by Western blot over
a differentiation time course, as well as, in biological quadruplicate at DD3. Overexpression of
Fam83d significantly reduced whole protein and phosphorylation levels of AKT at all time
points assessed (Fig. 14A-D). To further evaluate the effect of Fam83d on the AKT signaling
pathway, mTOR protein and phosphorylation levels were also investigated. Interestingly, at 3
days of differentiation, Fam83d overexpression had no significant effect on total mTOR protein
or phosphorylation of S2448, which is a primary target residue for AKT phosphorylation. GSK3β, another downstream target of AKT signaling, was also evaluated and no significant effect at
the whole protein level was observed in response to ectopic expression of Fam83d, while a small
but significant repression in phosphorylation levels in response to Fam83d overexpression was
observed (Fig. 14A-D).
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Figure 14. Ectopic expression of Fam83d inhibits AKT signaling in muscle cells. (A) C2C12 cells
were transfected with a Fam83d-myc-Flag expression plasmid or mock transfected. Cells were
maintained in proliferation media (10% serum) and harvested 2 days post-plating and the
remaining cells were then switched to differentiation media (2% serum) and harvested 1, 3, and 5
days post-media change. Western blot analysis of phosphorylated-AKT (p-AKT), pan-AKT
(AKT), phosphorylated serine 2448-mTOR (p-S2448-mTOR), pan-mTOR (mTOR),
phosphorylated-GSK-3β (p-GSK-3β), and pan-GSK-3β (GSK-3β) using protein homogenates
from proliferating (PD2) and differentiated C2C12 cells. These experiments were repeated at least
three times (n = 3) and the Western blots shown are representative examples of the results
obtained. (B) C2C12 cells were transfected with a Fam83d-myc-Flag WT expression plasmid or
mock transfected in biological quadruplicates. Western blot analysis of phosphorylated-AKT (pAKT), pan-AKT (AKT), phosphorylated serine 2448 mTOR (p-S2448-mTOR), pan-mTOR
(mTOR), phosphorylated-GSK-3β (p-GSK-3β), and pan-GSK-3β (GSK-3β) using protein
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homogenates from C2C12 cells differentiated for 3 days. The experiment was performed in
quadruplicate (n =4), repeated at least three times, and the blots shown are representative
examples of the results obtained. (C) Quantification of the Western blot band intensities were
measured for AKT, mTOR, and GSK-3β. Relative intensity of each band was corrected to either
GAPDH or α-tubulin band intensities for each corresponding biological replicate. Significant
differences between control cells compared to cells ectopically expressing Fam83d-myc-Flag, (*:
P < .05, N.S. = not significant). (D) Relative intensity of the phospho-AKT to pan-AKT ratio, the
phospho-S2448-mTOR to pan-mTOR ratio, and the phospho-GSK-3β (p-GSK-3β) to pan-GSK3β (GSK-3β) ratio. Significant differences between control cells compared to cells ectopically
expressing Fam83d-myc-Flag, (*: P < .05, **: P < .01, N.S. = not significant).

Fam83d physically interacts with and destabilizes casein kinase 1α in muscle cells
Previous studies have demonstrated that Fam83 family members interact with casein kinase 1α
(CSNK1α1) and HMMR (31, 32, 33, 34).To investigate if these interactions occur in muscle
cells, co-immunoprecipitation (co-IP) was performed using protein lysates isolated from C2C12
myoblasts transfected with a Fam83d-myc-Flag expression plasmid and harvested 24 h posttransfection. Immunoprecipitation of the Fam83d protein revealed a strong interaction with
CSNK1α1 and HMMR (Fig. 15). To determine if the interactions between Fam83d and
CSNK1α1 and Fam83d and HMMR are dependent on the putative phospholipase D-like (PLD)
motif, lysates from C2C12 cells overexpressing the Fam83d-H239N/K241Q mutant protein were
also used for co-IP. Interestingly, mutation of the PLD-like motif significantly impaired the
Fam83d/CSNK1α1 interaction, but did not affect the Fam83d/HMMR interaction (Fig. 15).
Fam83d has also been shown previously to associate with Fbxw7 in colorectal cancer (30) and
breast cancer (22) but co-immunoprecipitation showed no evidence of a direct interaction
between Fam83d and Fbxw7 in skeletal muscle cells (Fig. 15).
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Figure 15. Fam83d physically interacts with casein kinase 1α. Fam83d directly interacts with
casein kinase Iα and HMMR but not Fbxw7 in muscle cells. Immunoprecipitation (IP) of
Fam83d from control C2C12 cells and cells overexpressing wild-type Fam83d-myc- Flag or
Fam83d-myc-Flag-H239N/K241Q double mutant followed by Western blotting for casein kinase
Iα, Fbxw7, HMMR, or Fam83d-Flag (top four panels). Western blot analysis confirmed
relatively equal casein kinase Iα, Fbxw7, HMMR, Fam83d, and GAPDH in cell lysates from
control C2C12 cells and cells overexpressing Fam83d-WT or Fam83d-H239N/K241Q (bottom
five panels).
To further investigate the affect Fam83d might have on CSNK1α1, HMMR, and Fbxw7 stability,
protein lysates from cells harvested over a differentiation time course and in biological
quadruplicates at DD3 were evaluated by Western blot. Overexpression of Fam83d-WT
significantly reduced CSNK1α1 protein levels at PD2 but did not appear to effect stability during
differentiation (Fig. 16A-C). In contrast, Fbxw7 and HMMR protein levels showed significant
elevation in response to Fam83d-WT ectopic expression later in differentiation (Fig. 16A-C).
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Figure 16. Overexpression of Fam83d destabilizes casein kinase 1α. (A) C2C12 cells were
transfected with a Fam83d-myc-Flag expression plasmid or mock transfected. Western blot
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analysis of casein kinase Iα, Fbxw7, and HMMR using protein homogenates from proliferating
(PD2) and differentiated (DD1, DD3, and DD5) C2C12 cells. The experiments were repeated at
least three times (n = 3) and the Western blots shown are representative examples of the results
obtained. GAPDH was analyzed to confirm equal protein loading. (B) C2C12 cells were
transfected with a wild-type Fam83d-myc-Flag expression plasmid or mock transfected in
biological quadruplicates. Western blot analysis of casein kinase Iα, Fbxw7, and HMMR using
protein homogenates from C2C12 cells differentiated for 3 days. The experiment was performed
in quadruplicate (n = 4), repeated at least three times, and the blots shown are representative
examples of the results obtained. GAPDH was analyzed to confirm equal protein loading. (C)
Quantification of the Western blot band intensities measured from part C. Significant differences
between control cells and cells ectopically expressing Fam83d, (**: P < .01, ****: P < .0001,
N.S. = not significant).
To determine if the PLD-like motif plays a role in CSNK1α1, HMMR, and Fbxw7 protein
stability, the Fam83d-H239N/K241Q mutant was overexpressed in cultured muscle cells and
harvested in biological quadruplicates at DD3. In contrast to wild-type Fam83d, Fam83dH239N/ K241Q overexpression resulted in significantly elevated levels of CSNK1α1, while
Fbxw7 levels remained unchanged compared to control cells (Fig.17A and B)). Furthermore, as
described above, AKT protein levels were found to be significantly repressed in response to
ectopic expression of wild-type Fam83d (Fig. 14B and C). Therefore, AKT protein levels were
also assessed using lysates harvested from cells ectopically expressing the Fam83d double
mutant and no significant change in expression of AKT was observed (Fig. 17A and B).
Interestingly, HMMR protein levels were elevated in cells overexpressing either Fam83d-WT
(Fig. 16B and C) or Fam83d-H239N/K241Q (Fig. 17A and B). These results suggest that the
mechanism by which Fam83d affects CSNK1α1, AKT, and Fbxw7 protein stability may depend
on the putative phospholipase D-like motif, while stabilization of HMMR may be independent of
the PLD-like motif.
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Figure 17. Fam83d effect on casein kinase 1α stability is PLD-like motif dependent. (A) C2C12
cells were transfected with the Fam83d-H239N/K241Q double mutant expression plasmid or
mock transfected in biological quadruplicates. Western blot analysis of casein kinase Iα, Fbxw7,
HMMR, and AKT using protein homogenates from C2C12 cells differentiated for 3 days. The
experiment was performed in quadruplicate (n = 4), repeated at least three times, and the blots
shown are representative examples of the results obtained. GAPDH was analyzed to confirm
equal protein loading. (B) Quantification of the Western blot band intensities measured from part
A. Significant differences between control cells and cells ectopically expressing Fam83dH239N/K241Q, (*: P < .05, N.S. = not significant).
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Finally, to support the hypothesis that the putative PLD-like motif likely plays a role in
CSNK1α1 stability and ERK1/2 phosphorylation levels, a second Fam83d mutant, Fam83dF280A, was generated. Mutation of F280 has previously been shown to abolish the Fam83dCSNK1α1 interaction (32, 33). Co-immunoprecipitation assays demonstrate that the Fam83dF280A mutant has diminished CSNK1α1 binding ability in muscle cells (Fig. 18A).
Furthermore, unlike the Fam83d PLD-like motif mutant, overexpression of the Fam83d-F280A
mutant did not lead to increased levels of CSNK1α1 in differentiated C2C12 cells (Fig. 18B and
C). Additionally, ectopic expression of the Fam83d-F280A mutant caused significant repression
of ERK1/2 phosphorylation (Fig. 18B and C), which matches the results obtained for Fam83dWT (Fig. 13C and D), but not the Fam83d PLD-like motif mutant (Fig. 13E and F).
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Figure 18. Fam83d-F280A mutant inhibits ERK1/2 phosphorylation and does not destabilize
casein kinase 1α. (A) Fam83d-F280A does not interact with casein kinase Iα.
Immunoprecipitation (IP) of Fam83d from control C2C12 cells and cells overexpressing wildtype Fam83d-myc-Flag, Fam83d-myc-Flag-H239N/K241Q double mutant, or Fam83d-mycFlag-F280A mutant followed by Western blotting for casein kinase Iα or Fam83d-Flag (top two
panels). Western blot analysis confirmed relatively equal casein kinase Iα, Fam83d, and GAPDH
in cell lysates from control C2C12 cells and cells overexpressing Fam83d-myc-Flag WT,
Fam83d-myc-Flag-H239N/K241Q, or Fam83d-myc-Flag-F280A (bottom three panels). (B)
C2C12 cells were transfected with a Fam83d-myc-Flag-F280A mutant expression plasmid or
mock transfected in biological quadruplicates. Western blot analysis of Fam83d, phosphoERK1/2, pan-ERK1/2, CSNK1α1, HMMR, and AKT using protein homogenates from C2C12
cells differentiated for 3 days (DD3). The experiment was performed in quadruplicate (n = 4),
repeated at least three times, and the blots shown are representative examples of the results
obtained. GAPDH was analyzed to confirm equal protein loading. (C) Quantification of the
46

Western blot band intensities measured from part B. Significant differences between control cells
compared to cells ectopically expressing Fam83d-myc-Flag-F280A, (***: P < .001, ****: P <
.0001, N.S. = not significant).
Inhibition of ERK1/2 and MEK1/2 stabilizes Fam83d during muscle cell differentiation
As noted above, ectopic expression of Fam83d in C2C12 results in a high level of expression
during proliferation and then rapidly decreases as cells begin to differentiate (Fig. 9C and D).
Since Fam83d inhibits the ERK1/2 branch of the MAP kinase signaling pathway, and inhibition
of ERK1/2 or MEK1/2 causes pre-mature differentiation of C2C12 cells, we evaluated if
inhibition of ERK1/2 or MEK1/2 using small molecule inhibitors might impact Fam83d stability
during muscle cell differentiation. To answer this question, C2C12 cells were transfected with a
Fam83d-myc-Flag expression plasmid and treated with increasing concentrations of either
GSK1120212 (MEK inhibitor) or SCH772984 (ERK inhibitor) 24 h post-transfection and again
at the switch to differentiation media. Cells were then harvested 24 h posttreatment and protein
lysates were analyzed by Western blot. Fam83d protein levels were significantly elevated in
response to both the MEK1/2 and ERK1/2 inhibitors (Fig. 19A-E). Furthermore, stabilization of
Fam83d using the ERK1/2 and MEK1/2 inhibitors also resulted in significantly elevated levels
of CSNK1α1 and AKT in muscle cells (Fig. 19B-E).
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Figure 19. Inhibition of the MAP kinase signaling pathway stabilizes Fam83D. (A) C2C12 cells
were transfected with a wild-type Fam83d-myc-Flag expression plasmid and cells were then
treated with either the MEK1/2 inhibitor GSK1120212 (2.5 μM, 5 μM or 10 μM) or the ERK1/2
inhibitor SCH772984 (1 μM. 2 μM or 4 μM) or vehicle alone 24 h post-transfection. Western
blot analysis of Fam83d-myc-Flag using protein homogenates from cells differentiated for 1 day.
α-tubulin was analyzed to confirm equal protein loading. (B) C2C12 cells were transfected with a
wild-type Fam83d-myc-Flag expression plasmid and then treated with either SCH772984 (4 μM)
or vehicle alone 24 h post-transfection and differentiated for 1 day. Western blot analysis of
Fam83d-myc-Flag, casein kinase Iα, and AKT using protein lysates from cells differentiated for
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1 day. The experiment was performed in quadruplicate (n = 4), repeated at least three times, and
the blots shown are representative examples of the results obtained. α-tubulin was analyzed to
confirm equal protein loading. (C) Quantification of the Western blot band intensities measured
from part B. Significant differences between control cells and cells treated with SCH772984, (*:
P < .05, **: P < .01, ****: P < .0001). (D) C2C12 cells were transfected with a wild-type
Fam83d-myc-Flag expression plasmid and then treated with either GSK1120212 (5 μM) or
vehicle alone 24 h post-transfection and differentiated for 1 day. Western blot analysis of
Fam83d-myc-Flag, casein kinase Iα, and AKT using protein lysates from cells differentiated for
1 day. The experiment was performed in quadruplicate (n = 4), repeated at least three times, and
the blots shown are representative examples of the results obtained. α-tubulin was analyzed to
confirm equal protein loading. (E) Quantification of the Western blot band intensities measured
from part D. Significant differences between control cells and cells treated with GSK1120212,
(**: P < .01).
Discussion
Skeletal muscle is unique among body tissues due to its high degree of plasticity and its ability to
regulate its size and mass (9, 35). Skeletal muscle mass is maintained by a balance between
protein synthesis and protein degradation and when this balance is shifted toward protein
degradation, atrophy occurs (35). This imbalance can be triggered by a wide range of
physiological events including denervation, starvation, disease, disuse, and aging (9). While
there has been much work focused on degradation pathways, such as the ubiquitin proteasome
system, the molecular mechanisms that underly these disparate atrophy-inducing events remains
unclear. Fam83d has been identified as a novel molecular component of the atrophy cascade as it
is transcriptionally active in muscle and was found to be upregulated in response to neurogenic
atrophy (5). Fam83d has been previously studied in a variety of cancer models but this is the first
study to examine its role in muscle.

To characterize the expression and regulation of Fam83d in muscle, qPCR was conducted using
cDNA generated from C2C12 mouse myoblasts over a differentiation time course. These results
showed that Fam83d is highly upregulated during myoblast proliferation and is significantly
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down regulated as the cells proceed through differentiation. In addition, a Fam83d reporter gene
was found to be highly active in proliferating muscle cells and was repressed by ectopic
expression of MyoD, a myogenic regulator factor (MRFs) that is capable of binding canonical Ebox elements such as those found in the proximal promoter region of Fam83d. Muscle
development is a highly ordered process controlled by a concert of myogenic regulatory factors
being expressed at specific stages of muscle cell development (36). Myf5 is the first MRF to be
expressed in satellite cells, which commits them to the muscle cell lineage. MyoD expression
follows shortly thereafter, in a semi-redundant role, to further push cells toward muscle cell
development. Finally, as MyoD expression rises in proliferating myoblasts myogenin and MRF4
are transcriptionally activated, which subsequently promotes muscle cell differentiation and
myotube formation (36). Therefore, the transcriptional repression of Fam83d during muscle
differentiation is likely MRF-dependent and might be a necessary step in muscle development. In
support of the qPCR data, endogenous Fam83d protein levels were found to decrease
significantly as cultured muscle cells transitioned from proliferating myoblasts to differentiated
myotubes.

Ectopic expression of myc-tagged Fam83d fusion protein was also found to be highly expressed
during proliferation and then rapidly turned over, which matches the endogenous Fam83d
expression pattern in muscle cells. Furthermore, treatment with MG132 stabilized Fam83d
expression during differentiation suggesting Fam83d is actively degraded by the 26S proteasome
as muscle cell differentiation progresses. These findings together suggest that Fam83d may have
a muscle-specific role with a narrow window of activity during the proliferative stage of muscle
development and is then transcriptionally downregulated and
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proteolytically degraded as cells enter differentiation. This is in agreement with previous
findings in several models of cancer where Fam83d was found to be a cell-cycle related gene and
alterations in its expression effected cell proliferation (22, 25, 29, 30, 31). Additionally, Fam83d
has previously been shown to be co-expressed with several mitosis-related genes (37).

To better understand the function of this gene in skeletal muscle, Fam83d was overexpressed and
protein lysates were compared to those from control cells via Western blot. It was found that
ectopic expression of Fam83d inhibited myogenic differentiation, as determined by significant
decreases of both myogenin and myosin heavy chain at all time points of differentiation tested. It
is important to note that C2C12 cells proliferate as myoblasts until they reach a confluent
monolayer and then fuse and differentiate into multinucleated myotubes on the culture plate
under reduced serum conditions. Therefore, if Fam83d were driving C2C12 cell proliferation as is
observed in many cancer cell models, it would be expected that myoblasts overexpressing
Fam83d would differentiate more quickly than cells not overexpressing Fam83d.

Furthermore, signaling pathways involved in myogenesis have been extensively studied and it is
well established that perturbations in these pathways can impair, delay or prevent muscle cell
differentiation and tissue development (11) One such pathway is the mitogen-activated protein
(MAP) kinase pathway. This pathway has four canonical branches, including extracellular
signal-regulated kinase 1/2 (ERK1/2), p38, c-Jun N terminal kinase (JNK), and ERK5 (10). As
Fam83d overexpression significantly inhibits myogenic differentiation, we hypothesized it may
be acting though inhibition of the MAP kinase pathway. Indeed, Fam83d overexpression
significantly reduced ERK1/2 phosphorylation, while ERK1/2 protein levels were also reduced,
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albeit to a lesser extent. Interestingly, MEK1/2 protein levels were not affected by Fam83d
overexpression, while phosphorylation status of MEK1/2 was only mildly inhibited by Fam83d
ectopic expression. To confirm that Fam83d-mediated inhibition of ERK1/2 phosphorylation
results in a change in the MAPK signaling cascade, we evaluated the activity of the downstream
transcription factor AP-1. When C2C12 cells were transfected with increasing concentrations of
Fam83d, we saw a corresponding decrease in the activity of an AP-1 reporter gene in a dosedependent fashion. Taken together, this data suggests that Fam83d inhibits MAPK signaling
specifically though the ERK1/2 branch by imposing its effects downstream of MEK1/2. Previous
studies have also observed an effect of Fam83d on MAPK signaling. In hepatocellular carcinoma
cell culture, Fam83d overexpression was shown to increase phosphorylation levels of both
MEK1/2 and ERK1/2 (25). Another study investigating the role of Fam83d in ovarian cancer
saw a similar increase in ERK1/2 phosphorylation when Fam83d was overexpressed in cell
culture (38). The findings of this study provide further evidence for the involvement of Fam83d
in the ERK branch of MAPK signaling but suggest the mechanism of that involvement may be
different between skeletal muscle and various cancer types. This is not wholly unexpected as
cancer represents an aberration of normal cell signaling. The ERK1/2 branch of the MAP kinase
pathway is active during myoblast proliferation, decreases as cells differentiate, and then peaks
again at terminal differentiation and during myoblast fusion (11). As Fam83d expression is
highest during proliferation, it is possible that Fam83d is influencing this first phase of ERK1/2
activation. Since expression of both proteins decrease as cells enter differentiation, we evaluated
the effect of MEK and ERK inhibition though the use of the small molecule inhibitors
GSK1120212 or SCH772984, respectively. Data from this experiment revealed that inhibition of
MEK or ERK was sufficient to significantly increased Fam83d levels during muscle cell
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differentiation. This suggests there may be some coordination of protein turnover involving both
Fam83d and the ERK1/2 branch of the MAPK signaling pathway as each appears to inhibit the
other.

Another important molecular component of muscle development and growth is the AKT
signaling pathway. AKT is a kinase that is activated in response to insulin signaling and can
modulate the activity of several downstream targets, including mTOR and GSK-3β (11).
Phosphorylation of mTOR by AKT is an activating event that leads to an increase in protein
synthesis. GSK-3β has been shown to inhibit differentiation and hypertrophy and
phosphorylation by AKT relieves this inhibition (11). To further elucidate the function of
Fam83d, we investigated its possible role in the AKT pathway. Overexpression of Fam83d
greatly reduced both total AKT protein levels, as well as, the amount of phosphorylated AKT in
C2C12 cells. Surprisingly, Fam83d overexpression did not significantly reduce mTOR
phosphorylation at serine 2448, the primary site of AKT phosphorylation. Overexpression of
Fam83d did not appear to effect GSK-3β protein levels, but did cause a small, but significant
decrease in GSK-3β phosphorylation levels.

These data suggest Fam83d may have a role in negatively regulating AKT activity as part of the
atrophy cascade. Interestingly, other investigations have also found Fam83d to be involved in
AKT signaling (22, 29). A study looking at the role of Fam83d in breast cancer showed that
overexpression of Fam83d increased the amount of mTOR phosphorylation (22). Another study
investigating ovarian cancer also observed an increase in AKT and mTOR phosphorylation in
response to Fam83d overexpression (29). As with the results from the effect of Fam83d on
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ERK1/2 signaling, these results suggest that Fam83d is working via a different mechanism in
skeletal muscle than in cancers.

Fam83d is one of an eight-member family of proteins that all have DUF1669 in common, which
is a domain of unknown function located at the N-terminus of each protein. While the amino acid
sequence of this highly conserved region provides few clues as to the function of the domain, it
does contain an HxKxxxxD (HKD) motif that is characteristic of a phospholipase D-like (PLDlike) domain (39). Typically, proteins that have phospholipase D catalytic activity contain two
PLD domains, and these domains interact to form the catalytic core within the protein (39).
Fam83d contains only one such HKD motif and, to date, there is no evidence that Fam83d
possess canonical PLD activity. A recent study found that DUF1669 was both necessary and
sufficient for the association between Fam83 family members and members of the casein kinase
1 (CSNK1) family, which has resulted in a proposed renaming of DUF1669 to polypeptide
anchor of casein kinase 1 (PACK1) (32). This same study demonstrated that different CSNK1
isoforms have affinity for specific Fam83 family members, and Fam83d was shown to associate
specifically with CSNK1α1 and CSNK1α1-like (32).

To further elucidate the role of Fam83d in skeletal muscle, co-immunoprecipitation experiments
using C2C12 cells revealed that Fam83d does indeed associate with CSNK1α1. To investigate the
mechanism of this interaction, site-directed mutagenesis was used to create a double mutation
within the HKD motif resulting in the creation of the Fam83d- H239N/K241Q mutant (Fig. 11A,
green asterisks signify mutated amino acids). Disruption of the HKD motif significantly
diminished the interaction between Fam83d and CSNK1α1 in muscle cells. Interestingly,
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overexpression of Fam83d-H238N/K241Q resulted in a significant increase in CSNK1α1 levels
in differentiated myotubes, while overexpression of Fam38d-WT led to significant
destabilization of CSNK1α1 in proliferating myoblasts. A recent study examined FAM83D and
CSNK1α1 binding in the human osteosarcoma cell line U2OS by mutating two different amino
acids also contained within DUF1669; F283A and D249A. Each of these substitutions on their
own were sufficient to ablate the Fam83d/CSNK1α1 interaction (33). These results together
suggest that the binding of CSNK1α1 to Fam83d likely involves numerous amino acids in the
DUF1669 region and that mutation of any of these residues greatly disrupts the interaction
between Fam83d and CSNK1α1. In the current study, we also generated a Fam83d-F280A
mutant (equivalent to the human FAM83D-F283A mutation) and found that the
Fam83d/CSNK1α1 interaction was significantly diminished. Interestingly, the Fam83d-F280A
mutant did not stabilize CSNK1α1 in differentiated myotubes as was observed with Fam83dH239N/K241Q double mutant overexpression. Furthermore, like wild-type Fam83d, the F280A
mutant was still able to inhibit ERK1/2 phosphorylation, while the H239N/K241Q mutant was
unable to inhibit ERK1/2 phosphorylation. These novel and intriguing observations suggest that
the putative PLD-like domain may play a functional role in CSNK1α1 stability and ERK1/2
phosphorylation in muscle cells.

The discovery that Fam83d is induced in response to denervation furthers our understanding of
the molecular genetic events of neurogenic atrophy. This study identifies Fam83d as having
novel, muscle specific, expression and function. Fam83d is both transcriptionally active and
highly expressed during myoblast proliferation and is rapidly downregulated and degraded as
cells begin differentiation. Fam83d overexpression negatively regulates both the ERK1/2 branch
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of MAP kinase signaling, as well as, AKT signaling. This regulation appears to involve the HKD
motif located within DUF1669 at the N-terminal region of the protein and disruption of this
motif reverses the negative effects. Fam83d also physically associates with and destabilizes
CSNK1α1 in skeletal muscle and this association and destabilization is at least partially mediated
by the HKD motif. Although further investigation is needed to elucidate the precise function of
this gene, this study furthers our current understanding of the molecular and cellular events of
muscle atrophy and suggests that Fam83d may play a functional role in muscle cell
differentiation, development, and atrophy.
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Chapter 3: Identification and Functional Analysis of Dual Specificity Phosphatase and Pro
Isomerase Containing 1 (Dupd1) in Skeletal Muscle

Introduction
Overview of Dupd1
Dupd1 is categorized as an atypical dual specificity phosphatase (DUSP) capable of
dephosphorylating both phosphotyrosine and phosphoserine/phosphothreonine residues within
the same substrate (40). Dupd1 is evolutionarily conserved, sharing 87% identity with human
and 91% identity with rat (41). In mice, Dupd1 is highly expressed in skeletal muscle, liver and
adipose tissue (41). Interestingly, the human mRNA of Dupd1 has only been detected in skeletal
muscle (http://www.proteinatlas.org/ENSG00000188716-DUPD1/tissue). When the open
reading frame associated with Dupd1 was initially identified, it was predicted to include a
proline isomerase and a DUSP region but further investigation showed the transcript does not
include the proline isomerase, making dual specificity phosphatase and pro isomerase domain
containing 1 a bit of a misnomer (41). Dupd1 was renamed to Dusp27 in a 2007 paper, causing
confusion with another atypical DUSP that is identified by the same name (41). For clarity, the
subject gene of this study will continue to be referred to as Dupd1 until the nomenclature has
been definitively determined. Dupd1 has been the focus of few previous studies and its role in
skeletal muscle atrophy is completely unknown. As a phosphatase, the role of Dupd1 may lie in
modulation of intracellular signaling.

Materials and Methods
Cell Culture
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The C2C12 immortalized mouse myoblast cell line was obtained from the American Type Culture
Collection (Manassas, VA) and maintained in DMEM (Life 163 Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS) (GE164 Healthcare HyClone
Laboratories, Logan, UT), non-essential amino acids, gentamicin, penicillin and streptomycin
(all from Life Technologies, Grand Island, NY). Cells were grown in a humidified chamber at
37⁰C at 5% CO2. Cells were switched to DMEM supplemented with 2% serum, non-essential
amino acids, gentamicin, penicillin and streptomycin 48 hours post-plating to stimulate myotube
differentiation (Waddell, 2016).

RNA Isolation and cDNA synthesis
Total RNA was isolated from C2C12 myoblast cells using the RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer's protocol. Purified RNA (1µg) was reversetranscribed using Oligo-dT primers and Moloney Murine Leukemia Virus (M-MLV) Reverse
Transcriptase according to the manufacturer's protocol (Life Technologies, Grand Island, NY)

Amplification and cloning of the full length Dupd1 cDNA
For the amplification of Dupd1 cDNA, gene-specific primer pairs were designed (see Table 1)
using the gene sequences from Mus musculus (GenBank accession number: NM_001013826).
PCR was performed according to the manufacturer's protocol (Life Technologies, Grand Island,
NY) using Taq DNA polymerase, and template prepared by reverse transcription of RNA
isolated from C2C12 cells as described above utilizing gene specific primer pairs (Table 1).
Amplicons were cloned into the pGEM-T Easy vector (Promega, Madison, WI) according the
manufacturer's protocol and sequenced using the Big Dye Sanger terminator sequencing method
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(Eurofins MWG Operon, Huntsville, AL) to confirm amplification of the expected target and the
absence of mutations. The Dupd1 cDNA was sub-cloned into the Xho1 and Bam HI restriction
sites of pcDNA3.1 (+) (Life Technologies, Grand Island, NY) and sequenced to confirm correct
orientation. The Dupd1 cDNA was also sub-cloned into the Xho1 and Bam HI restriction sites of
the pEGFP-C3 expression plasmid (Clontech, Mountain View, CA) and sequenced to confirm
correct orientation and in frame fusion with GFP. The Dupd1 cDNA fused to myc and DDDDK
tags and cloned into the pCMV6-Entry vector was purchased from OriGene Technologies
(Rockville, MD)..

Promoter cloning of the Dupd1 gene
Genomic DNA was isolated from C2C12 cells using the DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA) according to the manufacturer's protocol and used as template for the
amplification of the proximal regulatory region of Dupd1. PCR was performed using Dupd1
promoter region-specific primer pairs (see Table 1) developed using mouse genomic sequences
obtained from the Ensembl database (www.ensembl.org). PCR reactions were performed using
Taq DNA polymerase and genomic mouse DNA according to the manufacturer's protocol (Life
Technologies, Grand Island, NY). The PCR amplicons were cloned into the pGEM-T Easy
vector (Promega,Madison,WI) according to the manufacturer's protocol and sequenced to
confirm amplification of the predicted target region and the absence of mutations. The Dupd1
promoter fragments (~500, ~1000 and ~2000 base pairs) were sub-cloned into the Mlu I and
Hind III sites of the pSEAP2-Basic reporter plasmid (Clontech, Mountain View, CA) to create
the pSEAP-Dupd1-Pro500, the pSEAP-Dupd1-Pro1000 and the pSEAP-Dupd1-Pro2000 reporter
plasmids and sequenced to confirm correct orientation.
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Transfections
C2C12 myoblast cells were plated into 12 well plates at a density of 75,000 cells/well in DMEM
+ 10% FBS (proliferation media) and cultured overnight. All conditions were assessed in
triplicate. Transfections were performed utilizing Turbofect Transfection Reagent (Thermo
Scientific, Rockford, IL) following the manufacturer’s protocol. Media was refreshed 1 hour
prior to transfection. 1 μg of total DNA (250 ng/well of reporter plasmid, 125 ng/well of β galactosidase (β-gal) as the internal control plasmid, and empty pBluescript vector as filler DNA
to 1 μg DNA/well) was allowed to complex with transfection reagent for 20 minutes prior to
overlaying the cells. Following 24-hour incubation with the transfection reaction, the
proliferation media was replaced with differentiation media (DMEM + 2% serum) and incubated
for an additional 1-7 days until reporter assays were performed.

SEAP reporter gene assays
Growth media was collected from C2C12 mouse myoblasts at 1-7 days after the switch to
differentiation media post-transfection and tested for SEAP levels using the Phospha‐Light
SEAP Reporter Gene Assay Kit and following the manufacturer’s instructions (Life
Technologies, Grand Island, NY). The level of SEAP generated luminescence was assessed with
a Synergy 2 microplate reader programmed for an endpoint read and a 2 s integration time. At
the conclusion of the experiment, cells were lysed with Passive Lysis Buffer (Promega, Madison,
WI), lysates were centrifuged to clear cell debris, and assessed for β‐galactosidase (β‐gal)
activity. The SEAP activity numbers were corrected with β‐gal activity numbers to adjust for any
variation in transfection levels between wells.
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Bioinformatic analysis of Dupd1
DNA sequences corresponding to the promoter regions of human, rat, and mouse Dupd1
(Ensembl Transcript ID: ENSG00000188716.5, ENSRNOG00000013034.5, and
ENSMUSG00000063821.6, respectively) starting at ‐2000 and including the first exon were
taken from the Ensembl database (www.ensembl.org) and analyzed using the Clustal Omega
multiple sequence alignment tool available on the EMBL‐EBI website
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The Clustal Omega alignment data was then
analyzed using Boxshade version 3.21 (http://www.ch.embnet.org/software/BOX_form.html)
that is available on the ExPASy (www.expasy.org) website. The polypeptide sequences for
human, mouse, and rat Dupd1 were also downloaded from Ensembl and aligned using the
Clustal Omega alignment tool and shaded with Boxshade as described for the promoter
sequences above.

Quantitative PCR
Total RNA was isolated from proliferating and differentiated C2C12 cells as described above.
Purified total RNA (1.0 μg) was reverse‐transcribed using the iScript cDNA Synthesis Kit
according to the manufacturer’s protocol (Bio‐ Rad, Hercules, CA). cDNA amplification was
conducted using the iTaq Universal SYBR Green Reaction Supermix and gene specific primers
(see Table 1) according to the manufacturer’s protocol (Bio‐Rad, Hercules, CA). Samples were
analyzed using a CFX Connect Real‐Time PCR Detection System (Bio‐Rad, Hercules, CA) and
gene expression levels of Dupd1 at PD2, DD2 and DD7 were quantitated. Each timepoint was
performed in biological triplicates, each individual biological replicate was used for cDNA
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synthesis in duplicate, and each cDNA synthesis replicate was analyzed in technical triplicates
(three biological replicates × two cDNA synthesis replicates × three technical replicates = 18
individual reads per biological sample) and the experiment was repeated at least twice. Relative
gene expression was calculated using the 2−ΔΔCt Livak method and using GAPDH as the
reference gene.

Protein purification and Western blot analysis
C2C12 cells were cultured in 10 cm culture dishes and Dupd1 was exogenously expressed by
transfecting the cells with the pCMV6‐Dupd1-myc-DDK or pcDNA3.1-Dupd1 expression
plasmid 24 h post‐plating. The Dupd1 overexpression time course was collected by harvesting
cells 48 h post‐plating (PD2), as well as cells cultured for an additional 1, 3 or 5 days in
differentiation media (DD1, DD3, DD5). The collected cells were spun down and kept at −80°C
until cell homogenization and protein isolation was performed.

The harvested cells were incubated on ice for 30 min, with agitation every 10 minutes, in
Universal Lysis Buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP‐40), plus
additions (1 mM PMSF, 1 mM DTT, 10 mM β-glycerophosphate, 2 mM sodium molbydate, and
a protease inhibitor cocktail). Cell homogenates were centrifuged to clear cellular debris and
protein concentrations were determined using the Quick Start Bradford 1× Dye Reagent (Bio‐
Rad, Hercules, CA) following the manufacturer’s instructions.

Western blots were conducted using 75-100 μg of protein on a 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis denaturing gel and then transferring overnight to
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polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA). Membranes were stained
with Ponceau S to visualize equal protein loading and successful transfer and then incubated with
blocking solution (5% w/v dry milk in tris‐buffered saline with 0.05% Tween‐20). Western blot
membranes were incubated with antibodies listed in Table 2, followed by probing with an
appropriate HRP‐conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) and
visualized using ECL substrate (Pierce/Thermo Fisher Scientific, Rockford, IL). Polyvinylidene
difluoride (PVDF) membranes were stripped by incubating for 20-30 min in stripping buffer
(10% SDS, 0.5 M tris-HCl pH 6.8 and β-mercaptoethanol) at 50°C, and then blocked, probed,
and visualized again as described above. Western blot band intensity quantifications were
conducted using the open access ImageJ software.

Confocal Fluorescence Microscopy
C2C12 cells were plated on Cellvis (Sunnyvale, CA) 35 mm glass bottom dishes and transfected
24 h after cells were plated with either the pEGFP‐C3 or pEGFP‐Dupd1 plasmids duplexed with
TurboFect Reagent (Thermo Fisher Scientific, Rockford, IL) as per the manufacturer’s
instructions. Before imaging, the cells were washed with phosphate buffered saline, fixed with
paraformaldehyde dissolved in sodium cacodylate, and stained with DRAQ5 fluorescent DNA
dye (Biostatus, Leicestershire, UK). The images were acquired using an Olympus Fluoview FV‐
1000 confocal fluorescent microscope equipped with Super Apochromat UPLSAPO 20X and
Super Apochromat UPLSAPO 60XW objectives. Open access ImageJ software combined with
the Open Microscopy Environment Bio‐Formats plugin was used to analyze, merge, and save all
images.
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Co-immunoprecipitation
C2C12 cells were grown in 10% FBS DMEM media and transfected with pCMV6-Dupd1-mycDDK expression plasmid and harvested 24 hours post-transfection. Cells were lysed on ice for
30 minutes in ULB (+) (50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP-40, 1 mM
PMSF, 1 mM DTT, 10 mM β-glycerophosphate, 2 mM sodium molbydate, and protease
inhibitor cocktail). Homogenates were cleared by centrifugation and protein concentrations were
quantified using the Quick Start Bradford 1X Dye Reagent (Bio-Rad, Hercules, CA) according
to the manufacturer’s protocol. 500 μg protein was diluted in ULB and precleared with protein
A/G agarose beads (Pierce/Thermo Scientific, Rockford, IL) for 1 h at 4°C with constant endover-end rotation. Beads were cleared from solution via centrifugation and the supernatant was
incubated with 2 μg of anti-myc (60003-2-lg; ProteinTech, 318 Rosemont, IL) antibody for 4 h at
4°C with constant end-over-end rotation. Protein A/G agarose beads were added to solution and
incubation was continued for 6 additional hours. Beads were cleared from solution via
centrifugation and pelleted beads were washed 3X with ULB, and then boiled for 5 mins at
95°C. 50 μg of protein lysate was used for input control and SDS-PAGE was performed.
Separated proteins were then transferred to a PVDF membrane and probed using the antibodies
listed in Table 2. .

Statistics
Data are presented as the mean ± standard deviation (SD). Statistical analysis was conducted
using a two-tailed t-test and a difference was considered statistically significant at a P value <
0.05.
Table 3. List of primers used in the Dupd1 study
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Primer
Dupd1-cDNA-F1
Dupd1-cDNA-R1
Dupd1-cDNA-F2
Dupd1-cDNA-R2
Dupd1-C146A-F
Dupd1-C146A-R
Dupd1-pro500-F
Dupd1-pro1000-F
Dupd1-pro2000-F
Dupd1-pro-R
Dupd1-pro500-Ebox1-Mut-F
Dupd1-pro500-Ebox1-MutR
Dupd1-pro500-Ebox2-Mut-F
Dupd1-pro500-Ebox2-MutR
Dupd1-qpcr-F1
Dupd1-qpc-R1
Dupd1-qpcr-F2
Dupd1-qpc-R2

Sequence (5’-3’)
GCCTCGAGGCTGCCACACACCCTTCGGACTGG
GCGGATCCCCCCTACAGCCCTAGGTCACTGTCC
GCCTCGAGGGCTCCAAAATGGCATCAGGAGATA
GCGGATCCCCTTTTCCTTACCCAGATCCCCCTG
GATCCTGGTTCACGCTGCCATGGGCCG
CGGCCATGGCAGCGTGAACCAGGATC
GCACGCGTGAAGTGCTACCTGCACAGTGTTTGCCC
GCACGCGTGCATACCCGTCAGACCATCACCACACC
GCACGCGTCACTACTCCCAGGCCTCAGGGATTAGG
GCAAGCTTCTGGCTGGGCTAAGAGGTACCAGTCCG
CATCCTGGCGGCCGCACGTCCTGTATCTGTGG
CCACAGATACAGGACGTGCGGCCGCCAGGATG
TCATTTTGCAAACGAACGCCACGGGTCTCC
GGAGACCCGTGGCGTTCGTTTGCAAAATGA
GCACACAGAAAGGAAAGAACC
TACAGTAGTCCTCAGCATCTC
CACACGTCAATGAGGTCTGGC
ATGGCCATGTCTCGGTAGTAG

Table 4. List of antibodies used in the Dupd1 study
Antibody
Source
anti-Dusp27
Santa Cruz Biotechnology, Dallas, TX
anti-myc
ProteinTech, Rosemont, IL
anti-α-tubulin
anti-Myosin Heavy
Chain (MYH1/2/4/6)
anti-myogenin
anti-GAPDH
anti-phospho-ERK
anti-ERK
anti-Akt1-phosphoS473
anti-Akt
anti-phospho-mTORSer2448
anti-phospho-mTORSer2481
anti-mTOR
anti-phospho-4E-BP1
(Thr37/46)

Catalog #
Sc-515513
60003-2-lg

Santa Cruz Biotechnology, Dallas, TX
Santa Cruz Biotechnology, Dallas, TX

sc-32293
sc-32732

Dilution
WB: 1:250
WB: 1:2000
IF: 1:50
WB: 1:1000
WB: 1:1000

Santa Cruz Biotechnology, Dallas, TX
ProteinTech, Rosemont, IL
Santa Cruz Biotechnology, Dallas, TX
Santa Cruz Biotechnology, Dallas, TX
ProteinTech, Rosemont, IL

sc-12732
60004-1-lg
sc-7383
sc-94
66444-I-lg

WB: 1:1000
WB: 1:5000
WB: 1:1000
WB: 1:1000
WB: 1:2000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

60203-2-lg
5536

WB: 1:5000
WB: 1:2000

Cell Signaling Technology, Danvers, MA

2974

WB: 1:2000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

66888-1-lg
2855

WB: 1:10000
WB: 1:1000
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anti-4EBP1
Anti-phospho-p70 S6
Kinase (Thr389)
Anti p70(S6K)
anti-phospho-AMPKα
(Thr172)
anti-AMPK
anti-phosphoGlucocorticoid receptor
(Ser211)
Anti-Glucocorticoid
receptor
Anti-GFP tag
anti-DDK
Mouse anti-rabbit IgGHRP
Rabbit anti-mouse IgGHRP (H+L)

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

60246-1-lg
9205

WB: 1:2000
WB: 1:1000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

66638-1-lg
2535

WB: 1:4000
WB: 1:1000

ProteinTech, Rosemont, IL
Cell Signaling Technology, Danvers, MA

18167-1-AP
4161

WB: 1:2000
WB: 1:1000

ProteinTech, Rosemont, IL

66904-1-lg

WB: 1:5000

ProteinTech, Rosemont, IL
ProteinTech, Rosemont, IL
Santa Cruz Biotechnology, Dallas, TX

66002-1-lg
20543-1-AP
sc-2357

WB: 1:5000
WB: 1:5000
WB: 1:5000

Thermo Scientific, Rockford, IL

PI31450

WB: 1:5000

Results
Dupd1 is upregulated during neurogenic skeletal muscle atrophy
RNA was isolated from control and denervated mouse gastrocnemius and soleus muscles as
previously described (5) and an Illumina mouse‐6 v1.1 microarray was performed at 3 days and
14 days post-denervation. Analysis of the microarray data submitted to the NCBI Gene
Expression Omnibus (GEO) revealed a significant number of genes that show differential
expression patterns in response to neurogenic muscle atrophy. Many of these genes have not
previously been characterized in skeletal muscle nor implicated in atrophy. Dupd1 showed low
basal levels of expression in control gastrocnemius and soleus muscles. However, in the
denervated tissue, Dupd1 was shown to be significantly upregulated at day 3 and day 14 postdenervation as compared to control animals (Fig. 20A).
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Dupd1 is composed of three coding and one non-coding exons, is located on chromosome 14 in
mice, and shows strong architectural conservation between mouse, rat, and human (Fig. 20B).

Figure 20. Dupd1 is upregulated during skeletal muscle atrophy. A) Whole genome expression
analysis was conducted on triceps surae muscle from wild-type (WT) mice after 3 days (3D) and
14 days (14D) of denervation. Each condition represents the average expression from three
animals and error bars represent ±SD. White bars, controls (Con); black bars, denervated (Den).
Significant difference between denervated mice and control mice in the same group (**:P < .01).
B) Schematic of the Dupd1 transcript in mouse. Darkened rectangles represent the exons
containing the translated region, open rectangles represent exons containing the untranslated
regions, and the lines connecting these rectangles represent introns
Dupd1 is expressed during late muscle cell differentiation
To measure the transcriptional activity of Dupd1, total RNA was harvested from C2C12 mouse
myoblasts during proliferation (PD2), as well as an early (DD2) and late (DD7) differentiation
timepoints. cDNA synthesized from this RNA was used to conduct RT-qPCR using Dupd1
specific primers listed in Table 3. Two sets of primer pairs were utilized to compare expression
between an amplicon containing part of the non-coding first exon and an amplicon lacking any
of the non-coding first exon. The qPCR analysis showed Dupd1 mRNA levels to be substantially
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higher during late differentiation compared to either proliferation or early differentiation
timepoints for both primer pairs (Fig. 21).

Figure 21. Dupd1 is significantly upregulated during muscle cell differentiation. Dupd1 mRNA
increases significantly during late differentiation compared to either proliferation or early
differentiation. Quantitative polymerase chain reaction (qPCR) utilizing cDNA generated from
RNA isolated from C2C12 cells harvested at proliferation day 2 (PD2), differentiation day 2
(DD2) and differentiation day 7 (DD7). Cells were maintained in proliferation media (10%
serum) and harvested at 2 days post-plating and the remaining cells were switched to
differentiation media (2% serum) and harvested at 2- and 7-days post-media change. Significant
difference between Dupd1 expression in differentiated cells compared to Dupd1 expression in
proliferating cells (*:P < .05, **:P < .01, ****:P< .0001).
Dupd1 is regulated by Myogenic Regulatory Factors
To evaluate how the proximal promoter region of Dupd1 is regulated within muscle cells,
approximately 500 and 1000 base pairs of the promoter were cloned using the primers listed in
Table 2. The fragments were then fused to a secreted alkaline phosphatase (SEAP) reporter
plasmid to create the pSEAP-Dupd1-Pro500 andpSEAP-Dupd1-Pro1000 reporter constructs. The
constructs were then transfected into C2C12 mouse myoblasts and SEAP assays were preformed
48 hours after the change to differentiation media. Promoter activity was assessed by secreted
alkaline phosphatase activity. Both the 500 and 1000 base pair fragments show low endogenous
expression at DD2 (Fig. 22A). However, endogenous activity of the 500 and 1000 base pair
fragments were significantly upregulated at DD7 compared to the proliferation and early
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differentiation timepoints, mirroring the endogenous mRNA expression as determined by qPCR
(Fig. 22B). Interestingly, co-transfection with a MyoD or myogenin expression plasmid resulted
in dramatic induction of both the 500 and 1000 bp promoter fragments (Fig. 22A). Myogenic
regulatory factors, such as MyoD and myogenin, regulate gene transcription through interaction
with E-box consensus elements found in the promotors of muscle-specific genes. Bioinformatic
analysis of the first 500 base pairs of the promoter of Dupd1 revealed five such elements, two of
which are conserved between humans and rodents (Fig. 22C). Site-directed mutagenesis was
used to disrupt each of the two conserved E-box elements individually and in combination.
Disruption of either E-box resulted in a dramatic blunting of the induction of the Dupd1-Pro500
seen with MyoD overexpression, while disruption of both E-boxes simultaneously eliminated the
MyoD induction effect (Fig. 22D).
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Figure 22. Cloning and analysis of the proximal regulatory region of the Dupd1 gene locus. (A)
C2C12 myoblasts were transfected with reporter plasmids containing 500 bp or 1000 bp of the
Dupd1 promoter fused to the Secreted Alkaline Phosphatase (SEAP) reporter gene alone or in
combination with either a MyoD or myogenin expression plasmid. Each condition was
performed in triplicate and each experiment was repeated at least three times (n = 3). The graphs
are of a representative experiment and values correspond to the mean relative light unit (RLU)
values ±SD. Significant difference between the empty control reporter plasmid (pSEAP2-Basic)
and the pSEAP2-Dupd1 reporter constructs, (*: P < .0001). Significant differences between the
activities of the pSEAP2-Dupd1-Pro reporter constructs with and without MyoD or myogenin
ectopic expression (B) C2C12 myoblasts were transfected with a reporter plasmid containing the
SEAP reporter gene fused to either 500 bp or 1000 bp of the Dupd1 proximal promoter or an
empty reporter plasmid. Each condition was performed in triplicate and assays were performed at
PD2 and DD7. Numbers correspond to the mean relative light unit (RLU) values ±SD.
Significant difference between the reporter constructs activity at PD2 and reporter constructs
activity at DD7 (*: P < .0001). (C) Schematic and sequence alignment of the Dupd1 regulatory
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region. Promoter sequences from mouse, rat, and human Dupd1 (2000 base pairs upstream of the
transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Approximate positions of
putative transcription factor binding sites are indicated in the schematic of the Dupd1 regulatory
region at the top. Putative consensus E-box elements 5′-CANNTG-3′ (Red diamond, conserved
and yellow triangle, non-conserved) and TATA box (green square) are indicated. N represents
any nucleotide. Conserved nucleotides are highlighted in black, transitions are highlighted in
gray, and transversions are highlighted in white. (D) C2C12 myoblasts were transfected with the
pSEAP-Dupd1-Pro500 wild-type,pSEAP-Dupd1-Pro500-Ebox-1-Mutant, pSEAP-Dupd1Pro500-Ebox-2-Mutant, or pSEAP-Dupd1-Pro500-Ebox-1/2-Mutant reporter plasmids. The
media was then assayed for SEAP activity at 72 hours following the switch to differentiation
media. All conditions were performed in triplicate and each experiment was repeated at least
once. The graphs are of a representative experiment and numbers correspond to the mean relative
light unit (RLU) values ± SD. Significant differences between the activities of the pSEAPDupd1-Pro500 wild-type reporter constructs and the pSEAP-Dupd1-Pro500-Ebox mutant
reporter constructs, (*: P < 0.001).
Subcellular localization of Dupd1
Dupd1 is located on chromosome 14 in mice and encodes a protein of 220 amino acids with a
predicted molecular weight of 27 kDa. It contains a phosphatase domain with an active catalytic
motif (Fig. 23A). To further characterize Dupd1 in skeletal muscle, the cDNA was cloned and
fused to a GFP plasmid to allow for analysis of subcellular localization by confocal fluorescent
microscopy. C2C12 cells were transfected with either an empty GFP expression plasmid or the
Dupd1-cDNA-GFP expression plasmid and analyzed 24 hours post-transfection. The control
GFP expression plasmid shows uniform GFP localization throughout the cell (Fig. 23B, Panels
1-3). Cells transfected with Dupd1 fused to GFP also showed ubiquitous distribution throughout
the cell, (Fig. 23B, Panels 4-12). The Dupd1-GFP expression plasmid was sequenced to confirm
Dupd1 inframe fusion with GFP and correct orientation. C2C12 myoblasts were transfected with
either an empty GFP expression plasmid or the Dupd1-GFP construct and protein lysates were
used for Western blots.. Probing with an anti-GFP antibody demonstrated the correct shift in size
in the Dupd1 containing plasmid compared to GFP alone. These findings together confirm that
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the Dupd1-GFP expression plasmid is truly expressing GFP-tagged Dupd1 that localizes
throughout C2C12 mouse myoblasts (Fig. 23C).
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Figure 23. Dupd1 localizes to the cytoplasm and nucleus of myoblast cells. (A) Sequences of the
mouse, rat, and human Dupd1 protein were downloaded from the Ensembl database and aligned
using the ClustalW2 algorithm. Approximate position of the phosphatase domain is highlighted
in green with the active motif within that domain highlighted in blue. (B) Proliferating C2C12
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cells (PD2) transfected with the empty pEGFP-C3 expression vector were imaged at 10× (Panels
1–3) and uniform cellular localization of GFP was observed. Representative C2C12 cells
transfected with a pEGFP-Dupd1 expression plasmid were imaged at proliferation day 2 (PD2)
at 10× (Panels 4–6), 60× (Panels 7–9), and 100× (Panels 10–12) and uniform cellular
fluorescence was observed. Draq5, a cell permeable fluorescent DNA dye, was used to visualize
cell nuclei. (C) NIH3T3 cells were transfected with either an empty pEGFP expression plasmid
or pEGFP-Dupd1 expression plasmid. Cells were maintained in culture media and harvested 24
hours post-transfection. Protein samples (25 µg, 50 µg, and 100 µg) from each condition were
used for Western blot analysis and membranes were probed with an anti-GFP antibody.
Ectopic expression of Dupd1 impairs muscle cell differentiation
To investigate whether Dupd1 has an impact on muscle cell differentiation, C2C12 cells were
transfected with a myc-tagged Dupd1 expression plasmid. Cells were then harvested, over a time
course spanning proliferation (PD2) and several differentiation timepoints (DD1, DD3 and
DD5). Protein was isolated from cells and evaluated for expression of myosin heavy chain
(MyHC) and myogenin, canonical makers of muscle cell differentiation. Western blot analysis
showed significantly lower levels of both myogenin and MyHC at all time points analyzed, with
the greatest inhibition at DD3 (Fig. 24A). To quantify the amount of inhibition, Dupd1 was
overexpressed in biological quadruplicate and harvested at day 3 of differentiation. Lysates were
evaluated by Western blot and it was found that myogenin and MyHC expression were
significantly reduced in samples ectopically expressing Dupd1 (Fig. 24B and C). Analysis with
an anti-Flag antibody confirmed significant overexpression of Flag tagged Dupd1 in all
transfected samples. GAPDH was used to confirm equal protein loading and it expression
remained relatively constant between samples.

74

Figure 24. Ectopic expression of Dupd1 impairs muscle cell differentiation. C2C12 cells were
transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed by
Western blot analysis. (A) Western blot analysis of Flag, Myosin Heavy Chain (MyHC), and
myogenin using protein homogenates from proliferating (PD) and differentiated (DD) C2C12
cells harvested over a 5-day differentiation time course. Cells were maintained in proliferation
media (10% serum) and harvested 2 days post-plating and the remaining cells were then
switched to differentiation media (2% serum) and harvested at 1, 3 and 5-days post-media
change. GAPDH was analyzed to confirm equal protein loading. The experiments were repeated
at least three times and the Western blots shown are representative examples of the results
obtained. (B) C2C12 cells were transfected with a Dupd1-myc-Flag expression plasmid or mock
transfected in biological quadruplicates and cell lysates were then analyzed by Western blot for
Flag, MyHC, and myogenin. Cells were maintained in proliferation media then switched to
differentiation media (2% serum) for 3 days. GAPDH was analyzed to confirm equal protein
loading. The experiment was performed in quadruplicate (n = 4). (C) Quantification of the
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Western blot band intensities for Flag, MyHC, and myogenin in Part B. Relative intensity of
each band was corrected to either GAPDH (shown) or α-tubulin band intensities for each
corresponding biological replicate. Significant differences between control cells compared to
cells ectopically expressing Dupd1-myc-Flag, (****: P < .0001).

Ectopic expression of Dupd1 attenuates MAP Kinase and AMPK protein expression
As Dupd1 was previously shown to effect MAP kinase signaling though modulation of the
ERK1/2 cascade in ovarian tissue, its potential role in this pathway in skeletal muscle was
investigated (45). C2C12 cells were transfected with a reporter plasmid created by fusing the AP1 consensus element to a pSEAP-promoter plasmid in combination with increasing
concentrations of the pcDNA3.1-Dupd1 expression plasmid. SCH772984, a validated ERK1/2
inhibitor, was used as a positive control. Dupd1 overexpression repressed AP1 reporter activity
in a dose dependent fashion, with the highest concentration of Dupd1 expression plasmid
exhibiting a similar level of repression as SCH772984 (Fig. 25A). To further evaluate this effect,
Dupd1 was overexpressed in C2C12 mouse myoblasts and harvested over a differentiation time
course, as well as in biological quadruplicate as described above, and protein homogenates from
these cells were evaluated by Western blot. Protein levels of ERK1/2 were not significantly
different in Dupd1 overexpression samples. However, overexpression of Dupd1 reduced levels
of ERK phosphorylation at all timepoints (Fig. 25B and C). Interestingly, Dupd1 seemed to
effect p42 phosphorylation levels more than p44 phosphorylation.
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Figure 25. Ectopic expression of Dupd1 attenuates MAP Kinase signaling. (A) C2C12 cells were
transfected with an AP-1 reporter plasmid alone or in combination with 0.125 µg, 0.25 µg or
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0.50 µg of the Dupd1-myc-Flag expression plasmid or treated with 2 µM of SCH772984, a
validated ERK inhibitor. The media was then assayed for SEAP activity 48 h (DD2) following
the switch to differentiation media and SEAP numbers were normalized to β-galactosidase
activity to correct for variations in transfection efficiency. Each condition was performed in
triplicate and each experiment was repeated at least three times (n = 3). The graphs are of a
representative experiment and numbers correspond to the mean relative light unit (RLU) values
±SD. Significant differences between the activities of the pSEAP2-AP-1-Pro reporter construct
alone and in combination with either 2 µM SCH772984 or 0.5 µg Dupd1-myc-Flag expression
plasmid , (**: P < .01). (B) C2C12 cells were transfected with a Dupd1-myc-Flag expression
plasmid or mock transfected followed by Western blot analysis. Cells were maintained in
proliferation media (10% serum) and harvested 2 days post-plating and the remaining cells were
then switched to differentiation media (2% serum) and harvested 1, 3, and 5 days post-media
change. Western blot analysis of phosphorylated-ERK1/2 (p-ERK1/2), pan-ERK1/2 (ERK1/2)
using protein homogenates from proliferating (PD2) and differentiated C2C12 cells. The
experiments were repeated at least three times (n = 3) and the Western blots shown are
representative examples of the results obtained. (C) C2C12 cells were transfected with a Dupd1myc-Flag WT expression plasmid or mock transfected in biological quadruplicates. Western blot
analysis of phosphorylated ERK1/2 (p-ERK1/2) and pan-ERK1/2 (ERK1/2) using protein
homogenates from C2C12 cells differentiated for 3 days. The experiment was performed in
quadruplicate (n = 4), repeated at least three times, and the blots shown are representative
examples of the results obtained. (D) Quantification of the Western blot band intensities were
measured for pan-ERK1/2 and the phospho-ERK1/2 to pan-ERK1/2 ratio Significant differences
between control cells compared to cells ectopically expressing Dupd1, (**: P < .01, N.S. = not
significant).
A previous study found Dupd1interacts with AMPK (42). To evaluate if this relationship exists
in muscle cells, the effect of Dupd1 overexpression on AMPK protein levels was evaluated by
Western blot over a differentiation time course and AMPK protein levels were found to be
significantly lower in the Dupd1 overexpression samples at all time points (Fig. 26A). To
quantify this difference, control cells and cells overexpressing Dupd1 were harvested at DD3 in
biological quadruplicate, and AMKP protein levels were quantified, revealing a significant
decrease in total AMPK protein. Interestingly, the amount of AMPK phosphorylation is
relatively constant between control cells and Dupd1 overexpressing cells and, considering the
decrease in total AMPK, a significant increase in the ratio of AMKP phosphorylation in response
to Dusp1 overexpression was observed (Fig. 26B and C)
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Figure 26. Ectopic expression of Dupd1 attenuates AMPK signaling. C2C12 cells were
transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed by
Western blot analysis. Cells were maintained in proliferation media (10% serum) and harvested 2
days post-plating and the remaining cells were then switched to differentiation media (2%
serum) and harvested 1, 3, and 5 days post-media change. Western blot analysis of
phosphorylated-AMPK (p-AMPK) and pan-AMPK (AMPK) using protein homogenates from
proliferating (PD2) and differentiated C2C12 cells. The experiments were repeated at least three
times (n = 3) and the Western blots shown are representative examples of the results obtained.
(C) C2C12 cells were transfected with a Dupd1-myc-Flag WT expression plasmid or mock
transfected in biological quadruplicates. Western blot analysis of phosphorylated-AMPK (pAMPK) andpan-AMPK (AMPK) using protein homogenates from cells differentiated for 3 days.
The experiment was performed in quadruplicate (n = 4), repeated at least three times, and the
blots shown are representative examples of the results obtained. (D) Quantification of the
Western blot band intensities were measured for pan-AMPK and the phospho-AMPK to panAMPK ratio. Significant differences between control cells compared to cells ectopically
expressing Dupd1, (****: P < .0001).
Dupd1 modulates glucocorticoid receptor signaling
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As dexamethasone treatment was previously shown to affect Dupd1 expression in mouse skeletal
muscle, the role of Dupd1 on glucocorticoid signaling was evaluated (5). C2C12 mouse myoblasts
were transfected with a reporter plasmid created by fusing four GRE consensus elements to a
pSEAP-promoter plasmid in combination with increasing concentrations of the pcDNA3.1Dupd1 expression plasmid. Additionally, cells were treated with dexamethasone at DD6 for 12
hours prior to the assay to induce the GR signaling pathway. Activity of the pSEAP-4X-GRE
reporter plasmid increased with dexamethasone treatment, while Dupd1 overexpression
significantly reduced this induction in a dose dependent manner (Fig. 27A). The proximal
promoter region of MuRF1 contains a glucocorticoid response element (GRE), which has
previously been shown to enhance transcription of MuRF1 in skeletal muscle (17). To evaluate if
Dupd1 may be capable of regulating MuRF1, 500 base pairs of the proximal promoter region of
MuRF1 was fused to the pSEAP2-Basic reporter plasmid and transfected into C2C12 mouse
myoblasts in combination with pcDNA3.1-Dupd1 expression plasmid followed by 12 h of
dexamethasone treatment. Consistent with previous findings, dexamethasone significantly
increased the activity of the pSEAP-MuRF1-Pro500 reporter. Overexpression of Dupd1
significantly blunted this dexamethasone-dependent induction (Fig. 27B).
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Figure 27. Dupd1 attenuates GR signaling. (A) C2C12 cells were transfected with a pSEAP-4XGRE reporter plasmid alone or in combination with 0.125 µg, 0.25 µg or 0.50 µg of the Dupd1myc-Flag expression plasmid and 5 µM dexamethasone (Dex). The media was then assayed for
SEAP activity 48 h (DD2) following the switch to differentiation media and SEAP numbers were
normalized to β-galactosidase activity to correct for variations in transfection efficiency. Each
condition was performed in triplicate and each experiment was repeated at least three times (n =
3). The graphs are of a representative experiment and numbers correspond to the mean relative
light unit (RLU) values ±SD. (B) C2C12 cells were transfected with a MuRF1-Pro500 SEAP
reporter plasmid alone, with 5 µM Dex or in combination the Dupd1-myc-Flag expression
plasmid and Dex. SEAP activity was measured at DD2.
As noted previously, Dupd1 expression was repressed in rat muscle tissue following 72 hours of
dexamethasone treatment as evidenced by microarray (5). To assess if glucocorticoids can
transcriptionally regulate Dupd1 in muscle cells, C2C12 mouse myoblasts were grown in culture,
switched to differentiation media and then allowed to differentiate for six days. Starting at day
six, cells were treated with dexamethasone for 72 hours and then harvested. Total RNA isolates
were used to generate cDNA and qPCR was conducted to compare Dupd1 transcript levels
between control and dexamethasone treated cells (Fig. 28). Results demonstrate a significant
increase in Dupd1 mRNA levels following dexamethasone treatment.
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Figure 28. Dexamethsone treatment enhances Dupd1 mRNA expression. Quantitative
polymerase chain reaction (qPCR) utilizing cDNA generated from RNA isolated from C2C12
cells harvested at differentiation day 7 (DD7) with or without 72 h Dex. Cells were maintained in
proliferation media (10% serum) and 2 days post-plating were switched to differentiation media
(2% serum). Significant difference between endogenous Dupd1 expression compared to Dupd1
expression in dexamethasone treated cells (****:P< .0001).

To further investigate the relationship between Dupd1 and GR, Dupd1 was overexpressed in
C2C12 mouse myoblasts and harvested over a differentiation time course and protein
homogenates from these cells were evaluated by Western blot. Interestingly, Dupd1
overexpression increased GR protein levels and phosphorylation status at all differentiation time
points (Fig. 29A). To quantify this difference, control cells and cells overexpressing Dupd1 were
harvested at DD5 in biological quadruplicate. Quantification revealed that Dupd1 overexpression
significantly increases total GR protein levels, as well as GR phosphorylation. Comparison
between GR protein levels and phosphorylation status indicated that not only is there an increase
in GR protein levels, but there is also a significant rise in GR phosphorylation in response to
Dupd1 overexpression (Fig. 29B and C). Since GR exists within a chaperone complex while in
the cytoplasm, the level of one of the major components of this complex, heat shock protein 90
(HSP90), was also evaluated in biological quadruplicate at DD5 (Fig. 29B and C). Dupd1
overexpression appears to have no effect on the levels of HSP90 (Fig. 29B and C).
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Figure 29. Dupd1 overexpression increases GR protein and phosphorylation levels. (A) C2C12
cells were transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed
by Western blot analysis. Cells were maintained in proliferation media (10% serum) and
harvested 2 days post-plating and the remaining cells were then switched to differentiation media
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(2% serum) and harvested 1, 3, and 5 days post-media change. Western blot analysis of
phosphorylated-GR (p-GR) and pan-GR (GR) using protein homogenates from proliferating
(PD2) and differentiated C2C12 cells. The experiments were repeated at least three times (n = 3)
and the Western blots shown are representative examples of the results obtained. (B) C2C12 cells
were transfected with a Dupd1-myc-Flag WT expression plasmid or mock transfected in
biological quadruplicates. Western blot analysis of Flag (Dupd1-Flag), phosphorylated-GR (pGR), pan-GR (GR), and heat shock protein 90 (HSP90) using protein homogenates from C2C12
cells differentiated for 3 days. The experiment was performed in quadruplicate (n = 4), repeated
at least three times, and the blots shown are representative examples of the results obtained.
GAPDH was used to confirm equal protein loading. (C) Quantification of the Western blot band
intensities were measured for pan-GR, the phospho-GR to pan-GR ratio, HSP90, and Flag
(Dupd1). Significant differences between control cells compared to cells ectopically expressing
Dupd1 (**: P < .01, N.S. = not significant).

Discussion
Skeletal muscle is a uniquely dynamic tissue and has remarkable ability to regulate its size and
mass (9, 35). Skeletal muscle mass is maintained through a balance of protein synthesis and
protein degradation and when this balance is shifted toward protein degradation, atrophy occurs
(35). A wide range of events are capable of inducing this imbalance including denervation,
starvation, disease, disuse, and aging (9). Much of the research in recent years has focused on
degradation pathways, such as the ubiquitin proteasome system (UPS), however, the molecular
mechanisms that underly these disparate atrophy-inducing events remain unclear. Dupd1 has
been identified as a novel molecular component of the atrophy cascade as it is transcriptionally
active in muscle and has been observed to be upregulated in response to neurogenic atrophy (5).
There have been few previous studies that have focused on Dupd1 and this is the first to evaluate
its role in the context of skeletal muscle atrophy.

To characterize the regulation and expression of Dupd1 in muscle, qPCR was conducted using
cDNA from C2C12 mouse myoblasts over a differentiation time course. These results showed that
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Dupd1 is highly upregulated during late differentiation as compared to either proliferation or
early differentiation. Additionally, the proximal promotor region was found to have endogenous
expression that mirrors the transcription profile identified by qPCR. The promoter has low
endogenous activity during cell proliferation but is highly upregulated during late differentiation.
Additionally, even when endogenous activity is low the promotor has been shown to be highly
inducible by myogenic regulatory factors (MRFs), specifically MyoD, and to a lesser extent,
myogenin. MRFs can modulate activity of muscle-specific genes by binding of Ebox elements,
of which there are two conserved Eboxes located in the proximal promoter region of Dupd1 (43).
Disruption of either of these conserved Ebox sequences significantly diminishes the MyoD
dependent induction and disruption of both all but ablates MRF-mediated induction. MyoD and
myogenin are both is upregulated during muscle cell differentiation and act as a markers of
myogenic commitment to the skeletal muscle lineage (43). Notably, MyoD and myognin are also
significantly upregulated during neurogenic skeletal muscle atrophy, which may play a role in
the upregulation of Dupd1 during both these processes (44). These findings together suggest that
Dupd1 has a muscle-specific role and is highly sensitive to changes in the muscle cell
environment.

Dupd1 is shown here to have a dramatic negative impact on muscle cell differentiation as
evidenced by a stark decrease in both myosin heavy chain (MyHC) and myogenin protein levels,
both canonical markers of differentiation in skeletal muscle. To further explore this effect, we
evaluated the potential role of Dupd1 in several signaling pathways important for muscle cell
growth and development. Dupd1 was previously shown to effect MAPK signaling though
interaction with both the ERK1/2 and p38 branches of the pathway in ovary tissue (45). In the
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current study, we find Dupd1 overexpression to inhibit MAPK signaling as evidenced by
decreases in AP-1 reporter activity in C2C12 mouse myoblasts. Furthermore, Western blot
analysis demonstrated that ERK1/2 phosphorylation was also inhibited by Dupd1
overexpression. Interestingly, it appears there is a preference for dephosphorylation of ERK2
(p42) over ERK1 (p44), as shown by an increased effect on the level of phosphorylation
observed for the 42 kDa band compared to the signal to 44 kDa (Fig. 25B and C). Direct
interaction between ERK1/2 and Dupd1 and p38 and Dupd1 was demonstrated by coimmunoprecipitation using the ovarian cell line GG-CL (45). This interaction was not found in
C2C12 mouse myoblasts nor did Dupd1 overexpression have any significant effect on p38 protein
levels or its phosphorylation status (data not shown). Additionally, the effect of Dupd1
overexpression on ERK1/2 phosphorylation appears more moderate than effects in the ovary
(45). Taken together this suggests that the effect exerted by Dupd1 on MAPK signaling in
skeletal muscle may be less robust in skeletal muscle than in the ovary. Rather than a direct
physical interaction and potential dephosphorylation event, the effect observed in skeletal muscle
may be a result of a downstream affect or an effect on another signaling pathway that
tangentially regulates ERK1/2 signaling.

AMP-activated protein kinase (AMPK) is a master regulator of energy homeostasis in virtually
all eukaryotic cell types and is highly conserved across animals, plants, and yeast (46). As
skeletal muscle plays a large role in metabolic homeostasis it is not surprising that AMPK is
highly expressed in this tissue (46). AMPK is regulated by a wide variety of upstream signals
and, through phosphorylation of a variety of transcription factors and co-factors, influences many
pathways involved with both protein synthesis and protein degradation (46). Many residues on
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AMPK are capable of being phosphorylated and one of the key residues for active kinase activity
is Threonine 172 (47). AMPK becomes activated, primarily though phosphorylation of T172, in
response to cellular stress and in turn activates pathways aimed at conserving existing ATP
reserves, as well as increasing the supply of ATP (47). The current study demonstrates that
Dudp1 overexpression significantly reduces AMPK protein levels while simultaneously
increasing the proportionate amount of phosphorylation of T172. This increase in relative
phosphorylation may be a compensatory mechanism in response to decreased protein levels or
the result of a Dupd1-mediated dephosphorylation event that destabilizes hypophosphorylated
AMPK in muscle cells. Interestingly, AMPK has also been previously shown to down regulate
glucocorticoid receptor (GR) signaling, specifically through increasing phosphorylation at serine
211 on GR (48).

Glucocorticoids (GC) are key metabolic regulators in skeletal muscle (19). Increases in GCs
decrease protein synthesis and increase protein degradation leading to skeletal muscle atrophy
(19). A previous study identified Dupd1 and being downregulated 7.2-fold in mouse triceps
surae (TS) complexes during skeletal muscle atrophy induced by three days of systemic
treatment with dexamethasone, a synthetic glucocorticoid. (5). The current study demonstrated
that a Dupd1 reporter gene is transcriptionally upregulated by dexamethasone treatment, which is
mirrored by RT-qPCR data showing that Dupd1 is upregulated in differentiated C2C12 cells in
response to dexamethasone treatment. The discrepancy between the previous microarray study
and the findings shown here highlight the complexity of atrophy signaling and the possibility of
signaling pathway crosstalk that might be absent in a cell culture model. Despite these
differences, evaluation in cell culture still provides valuable insights into muscle-specific
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responses. Dupd1 overexpression has a dramatic effect on the glucocorticoid receptor. Total GR
protein levels are significantly increased and phosphorylation of S211 is also increased. In many
tissues, phosphorylation of S211 leads to a conformational change resulting in increased binding
to glucocorticoid response elements (GRE) (49). However, in neuronal cells, liver cells, skeletal
muscle, and adipose tissue, phosphorylation of the S211site has been shown to decrease
signaling (48). This latter outcome is what was observed in C2C12 cells in response to
overexpression of Dupd1, which resulted in an attenuation of the transcriptional activity of both
the apSEAP-4X-GRE reporter construct and a MuRF1-Pro500 reporter construct containing a
fragment of the MuRF1 promoter that includes a canonical GRE.

Inactive glucocorticoid receptors reside in the cytoplasm bound in heat shock protein 90
(HSP90) chaperone complexes (50). GR is activated by binding with glucocorticoids which
results in disassociation from the chaperone complex and translocation to the nucleus (50). Once
in the nucleus several GR-mediated responses are possible. GR may homodimerize and bind to
GRE consensus elements, enhancing transcription of the genes they are associated with (20).
Ligand-bound GR may also bind other transcription factors such as AP-1 or NF-κB to modulate
their transcriptional activity (20). Additionally, monomeric GR may bind negative GREs
(nGRE), resulting in transcriptional inhibition (20). Phosphorylation of GR either pre- or postligand binding plays a role in determining which of these pathways GR will participate in (20).
As a phosphatase, Dupd1 likely plays a role in the dynamic phosphorylation landscape regulating
GR activity, resulting in the significant results described by this study. As a transcription factor,
GR can have wide-ranging effects on the cellular signaling environment (51). GR can affect
MAPK signaling though interaction with AP-1, as previously mentioned, and has also been
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shown to inhibit ERK phosphorylation (51). It is possible that the reduction in ERK
phosphorylation described in the current study is a result of downstream GR effects rather than
direct dephosphorylation by Dupd1.

The finding that Dupd1 expression is affected by multiple atrophy inducing stimuli furthers our
understanding of the complex molecular signaling network that underlies this debilitating
condition. This study demonstrates that Dupd1 overexpression dramatically inhibits muscle cell
differentiation, possibly as a result of its effect on the multiple signaling pathways examined
here. When Dupd1 was first characterized, it was predicted to be involved in the regulation of
energy metabolism, based on its tissue expression profile (41). The current study supports that
initial prediction by implicating Dupd1 as modulating two major pathways important for
metabolic homeostasis; glucocorticoid receptor and AMP-activated protein kinase signaling.
Although the precise molecular mechanisms responsible for the function of Dupd1 remains
unclear, this study reveals Dupd1 as potentially having a role in muscle cell differentiation,
development, and atrophy, as well as identifies it as a novel modulator of GR activity.
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